KR20100010316A - Cosmetic composition for preventing skin aging - Google Patents
Cosmetic composition for preventing skin aging Download PDFInfo
- Publication number
- KR20100010316A KR20100010316A KR1020080071236A KR20080071236A KR20100010316A KR 20100010316 A KR20100010316 A KR 20100010316A KR 1020080071236 A KR1020080071236 A KR 1020080071236A KR 20080071236 A KR20080071236 A KR 20080071236A KR 20100010316 A KR20100010316 A KR 20100010316A
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- skin
- herbal extract
- extract mixture
- skin aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 167
- 239000002537 cosmetic Substances 0.000 title claims abstract description 68
- 230000009759 skin aging Effects 0.000 title claims abstract description 48
- 239000012676 herbal extract Substances 0.000 claims abstract description 66
- 230000004663 cell proliferation Effects 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 235000012907 honey Nutrition 0.000 claims abstract description 19
- 230000001737 promoting effect Effects 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 13
- 230000002503 metabolic effect Effects 0.000 claims abstract description 13
- 230000007760 free radical scavenging Effects 0.000 claims abstract description 9
- 230000037319 collagen production Effects 0.000 claims abstract description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000001508 sulfur Nutrition 0.000 claims abstract description 6
- 239000011593 sulfur Substances 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 241000208340 Araliaceae Species 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 66
- 230000000694 effects Effects 0.000 claims description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 47
- 238000009472 formulation Methods 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 14
- 230000032683 aging Effects 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 230000003712 anti-aging effect Effects 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 7
- 241000361919 Metaphire sieboldi Species 0.000 claims description 7
- 235000003373 curcuma longa Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 235000013976 turmeric Nutrition 0.000 claims description 7
- 244000144725 Amygdalus communis Species 0.000 claims description 6
- 235000020224 almond Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims 2
- 230000004151 fermentation Effects 0.000 claims 2
- 244000163122 Curcuma domestica Species 0.000 claims 1
- -1 more specifically Substances 0.000 abstract description 57
- 230000037303 wrinkles Effects 0.000 abstract description 28
- 230000037394 skin elasticity Effects 0.000 abstract description 17
- 210000003491 skin Anatomy 0.000 description 92
- 210000004027 cell Anatomy 0.000 description 21
- 238000002835 absorbance Methods 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 230000006872 improvement Effects 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 108010022452 Collagen Type I Proteins 0.000 description 16
- 240000004371 Panax ginseng Species 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 102000012422 Collagen Type I Human genes 0.000 description 15
- 239000012091 fetal bovine serum Substances 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 102000008186 Collagen Human genes 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 230000002292 Radical scavenging effect Effects 0.000 description 13
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 231100000002 MTT assay Toxicity 0.000 description 8
- 238000000134 MTT assay Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 206010015037 epilepsy Diseases 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000036570 collagen biosynthesis Effects 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 6
- 241001474374 Blennius Species 0.000 description 6
- 244000008991 Curcuma longa Species 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 6
- 108010014258 Elastin Proteins 0.000 description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000686 essence Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 230000019522 cellular metabolic process Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 229920002549 elastin Polymers 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 5
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000013599 spices Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 235000011511 Diospyros Nutrition 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 4
- 239000002221 antipyretic Substances 0.000 description 4
- 239000012888 bovine serum Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000001023 inorganic pigment Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000012860 organic pigment Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristoyl-sn-glycerol Natural products CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- 241000238366 Cephalopoda Species 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000002280 amphoteric surfactant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 3
- 229940093541 dicetylphosphate Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 102000034240 fibrous proteins Human genes 0.000 description 3
- 108091005899 fibrous proteins Proteins 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 2
- UWNADWZGEHDQAB-UHFFFAOYSA-N 2,5-dimethylhexane Chemical group CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 235000011446 Amygdalus persica Nutrition 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- PKRPFNXROFUNDE-LLVKDONJSA-N Byakangelicin Chemical compound O1C(=O)C=CC2=C1C(OC[C@@H](O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-LLVKDONJSA-N 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000533367 Cnidium officinale Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 244000055850 Diospyros virginiana Species 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000016094 Magnolia denudata Nutrition 0.000 description 2
- 240000005819 Magnolia denudata Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- SFBIZPBTKROSDE-UHFFFAOYSA-N octyl 2-hydroxypropanoate Chemical compound CCCCCCCCOC(=O)C(C)O SFBIZPBTKROSDE-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- PHVSWPDOXIQPTN-UHFFFAOYSA-N sedanonic acid Chemical compound CCCCC(=O)C1CCCC=C1C(O)=O PHVSWPDOXIQPTN-UHFFFAOYSA-N 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 1
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WYUFTYLVLQZQNH-UHFFFAOYSA-N 1-Ethyl-D-galactoside Natural products CCOC1OC(CO)C(O)C(O)C1O WYUFTYLVLQZQNH-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- OUZOBPPZPCBJAR-UHFFFAOYSA-N 14-methylpentadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C OUZOBPPZPCBJAR-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- WPIOBXGJZUSKGK-UHFFFAOYSA-N 16-methylheptadecyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C WPIOBXGJZUSKGK-UHFFFAOYSA-N 0.000 description 1
- MVUWRLHKGKEGSS-UHFFFAOYSA-N 16-methylheptadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C MVUWRLHKGKEGSS-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- QZJDYFVPLXBWTK-UHFFFAOYSA-N 2-(diethylamino)ethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCN(CC)CC QZJDYFVPLXBWTK-UHFFFAOYSA-N 0.000 description 1
- ZMXUPLNMYABPEB-UHFFFAOYSA-N 2-[[2-(dodecanoylamino)acetyl]amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)NCC(=O)NCC(O)=O ZMXUPLNMYABPEB-UHFFFAOYSA-N 0.000 description 1
- QUBNFZFTFXTLKH-UHFFFAOYSA-N 2-aminododecanoic acid Chemical compound CCCCCCCCCCC(N)C(O)=O QUBNFZFTFXTLKH-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- KNEFRHCUYCDKRK-UHFFFAOYSA-N 2-benzyl-3-phenylprop-2-enoic acid Chemical compound C=1C=CC=CC=1C=C(C(=O)O)CC1=CC=CC=C1 KNEFRHCUYCDKRK-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 1
- HTNFLUQQANUSLR-UHFFFAOYSA-N 2-octanoyloxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC(=O)CCCCCCC HTNFLUQQANUSLR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- QULIOZDJZXKLNY-UHFFFAOYSA-N 3,4,5-trihydroxy-2-propylbenzoic acid Chemical compound CCCC1=C(O)C(O)=C(O)C=C1C(O)=O QULIOZDJZXKLNY-UHFFFAOYSA-N 0.000 description 1
- ZYIFAFPFZXUPAX-UHFFFAOYSA-N 3-(dimethylamino)propyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCCN(C)C ZYIFAFPFZXUPAX-UHFFFAOYSA-N 0.000 description 1
- SDZHIRPZKXFSBX-UHFFFAOYSA-N 3-(dodecanoylamino)propanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCC(=O)NCCC(O)=O SDZHIRPZKXFSBX-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 241000758795 Aristolochiaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000751139 Beauveria bassiana Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- FTFSBTUNGWWUHI-UHFFFAOYSA-N CC(C(C(CO)(CO)CO)CC)(C)C Chemical compound CC(C(C(CO)(CO)CO)CC)(C)C FTFSBTUNGWWUHI-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- WYUFTYLVLQZQNH-JAJWTYFOSA-N Ethyl beta-D-glucopyranoside Chemical compound CCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WYUFTYLVLQZQNH-JAJWTYFOSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- PYVHTIWHNXTVPF-UHFFFAOYSA-N F.F.F.F.C=C Chemical compound F.F.F.F.C=C PYVHTIWHNXTVPF-UHFFFAOYSA-N 0.000 description 1
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241000007358 Magnolia biondii Species 0.000 description 1
- 235000014196 Magnolia kobus Nutrition 0.000 description 1
- 240000005378 Magnolia kobus Species 0.000 description 1
- 241000218394 Magnolia liliiflora Species 0.000 description 1
- 241000218296 Magnolia salicifolia Species 0.000 description 1
- 241000007370 Magnolia sprengeri Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- FHEZONATBQHEDB-UHFFFAOYSA-N Nardofuran Natural products CC12C(C)CCC=C2C(=O)C2OC(C)(C)C1C2O FHEZONATBQHEDB-UHFFFAOYSA-N 0.000 description 1
- 241000790228 Nardostachys jatamansi Species 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 241000975417 Oscinella frit Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000046342 Prorocentrum koreanum Species 0.000 description 1
- 241000081559 Protium robustum Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241001533172 Thladiantha dubia Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 241000792902 Valerianaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- PRLUQOOFPFWUKQ-KKTNLPSRSA-N [(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@@H]2[C@@]3(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@]21C PRLUQOOFPFWUKQ-KKTNLPSRSA-N 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- YRXGUZPUZBCGST-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone Chemical compound OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 YRXGUZPUZBCGST-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical class CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- VZWMKHUMEIECPK-UHFFFAOYSA-M benzyl-dimethyl-octadecylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 VZWMKHUMEIECPK-UHFFFAOYSA-M 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- PKRPFNXROFUNDE-UHFFFAOYSA-N biac-angelicin Natural products O1C(=O)C=CC2=C1C(OCC(O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- AGNCRIYGRWNVIF-UHFFFAOYSA-N calcium;2-(dodecanoylamino)acetic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCC(O)=O AGNCRIYGRWNVIF-UHFFFAOYSA-N 0.000 description 1
- CEGYXKLZALIAEI-UHFFFAOYSA-N calcium;2-(dodecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCS(O)(=O)=O CEGYXKLZALIAEI-UHFFFAOYSA-N 0.000 description 1
- YEFORLIOCBRMFS-UHFFFAOYSA-N calcium;2-(hexadecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O YEFORLIOCBRMFS-UHFFFAOYSA-N 0.000 description 1
- HOQGRRFKKLWWOO-UHFFFAOYSA-N calcium;3-(dodecanoylamino)propanoic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCC(O)=O HOQGRRFKKLWWOO-UHFFFAOYSA-N 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- HIAAVKYLDRCDFQ-UHFFFAOYSA-L calcium;dodecanoate Chemical compound [Ca+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O HIAAVKYLDRCDFQ-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YDQXYRCYDMRJGD-UHFFFAOYSA-N chloroform;phenol;thiocyanic acid Chemical compound SC#N.ClC(Cl)Cl.OC1=CC=CC=C1 YDQXYRCYDMRJGD-UHFFFAOYSA-N 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1
- 229940073724 cholesteryl isostearate Drugs 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- OFADGACXTNUQLM-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O OFADGACXTNUQLM-UHFFFAOYSA-N 0.000 description 1
- PHMQYKDOTWAOBI-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O PHMQYKDOTWAOBI-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- FPMPNVIMFPEKRN-UHFFFAOYSA-N hexyl 16-methylheptadecanoate Chemical compound CCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FPMPNVIMFPEKRN-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 description 1
- 229930182569 kanshone Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical class [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- YFGAFXCSLUUJRG-WCCKRBBISA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCCN=C(N)N YFGAFXCSLUUJRG-WCCKRBBISA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- DQJCHOQLCLEDLL-UHFFFAOYSA-N tricyclazole Chemical compound CC1=CC=CC2=C1N1C=NN=C1S2 DQJCHOQLCLEDLL-UHFFFAOYSA-N 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 description 1
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 생약 추출 혼합물을 함유하는 피부 노화 방지용 화장료 조성물에 관한 것으로 보다 구체적으로, 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 생약 추출 혼합물(이하 '가감천금단'이라 칭함)과 인삼, 지황 및 꿀로 이루어진 생약 추출 혼합물(이하 '가감경옥고'이라 칭함)과 행인, 과루근 및 백봉령으로 이루어진 생약 추출 혼합물(이하 '가감홍옥산'이라 칭함) 을 유효성분으로 함유하는 피부 노화 방지용 화장료 조성물에 관한 것이다. 본 발명의 화장료 조성물은 피부에 안전하고, 세포증식 및 대사 활성 증진, 프리 라디칼 소거, 콜라겐 생산촉진에 의한 피부 주름 개선과 피부 탄력 개선을 통하여 피부 노화를 방지 및 개선한다. The present invention relates to a cosmetic composition for preventing skin aging containing a herbal extract mixture, more specifically, herbal extract consisting of white paper, Dongguin, Cheongung, Dongle, Sessin, Kwakeuneun, Doin, Bark skin, Sinyi, saengsonghyang and Baeksijam Herbal extract mixture (hereinafter referred to as 'Gagamcheon Forbidden') and herbal extract mixture consisting of ginseng, sulfur and honey (hereinafter referred to as 'Gagamkyung Okgo') and herbal extract mixture consisting of passerby, fruit root and Baekbongryeong (hereinafter referred to as 'Gagam Hongoksan') It relates to a cosmetic composition for preventing skin aging containing as an active ingredient. The cosmetic composition of the present invention is safe for the skin, and prevents and improves skin aging by improving cell proliferation and metabolic activity, free radical scavenging, improving skin wrinkles and improving skin elasticity by promoting collagen production.
Description
본 발명은 생약 추출 혼합물을 함유하는 피부 노화 방지용 화장료 조성물에 관한 것으로 보다 구체적으로, 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 생약 추출 혼합물(이하 '가감천금단'이라 칭함)과 인삼, 지황 및 꿀로 이루어진 생약 추출 혼합물(이하 '가감경옥고'이라 칭함)과 행인, 과루근 및 백봉령으로 이루어진 생약 추출 혼합물(이하 '가감홍옥산'이라 칭함) 을 유효성분으로 함유하는 피부 노화 방지용 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition for preventing skin aging containing a herbal extract mixture, more specifically, herbal extract consisting of white paper, Dongguin, Cheongung, Dongle, Sessin, Kwakeuneun, Doin, Bark skin, Sinyi, saengsonghyang and Baeksijam Herbal extract mixture (hereinafter referred to as 'Gagamcheon Forbidden') and herbal extract mixture consisting of ginseng, sulfur and honey (hereinafter referred to as 'Gagamkyung Okgo') and herbal extract mixture consisting of passerby, fruit root and Baekbongryeong (hereinafter referred to as 'Gagam Hongoksan') It relates to a cosmetic composition for preventing skin aging containing as an active ingredient.
인체의 피부는 외부 환경에 직접적으로 노출되는 부위로서, 과도한 자외선이나 오염 물질 등에 노출되면 활성산소나 프리라디칼이 생성되며, 생성된 활성산소나 프리라디칼에 의해 홍반, 부종, 뾰루지, 따끔거림, 가려움 등의 피부 자극 및 염증반응이 유발된다. 이러한 원인들에 의해 생성된 피부 트러블은 미관상 문제가 될 뿐만 아니라, 염증 반응 과정에서 생성되는 물질들이 부수적으로 피부의 색소 침착을 일으키고, 피부 탄력 섬유의 붕괴를 촉진시켜 피부 주름의 증가에까지 영향을 미치는 등 피부 노화에까지 이르는 것으로 알려져 있다. 따라서 화장품에서 가장 관심을 갖고 연구하는 분야 중 하나가 어떻게 피부 노화를 지연할 수 있을까 하는 것이다. 피부 노화에 따라 외관상 최종적으로 나타나는 현상은 주름의 형성, 피부 탄력 저하, 노인성 반점의 형성 등이 있는데, 특히 주름 형성이 가장 대표적인 현상으로 받아들여지고 있다.The skin of the human body is a part directly exposed to the external environment, and when exposed to excessive ultraviolet rays or pollutants, free radicals or free radicals are generated, and erythema, edema, rashes, tingling, and itching by the generated free radicals or free radicals Skin irritation and inflammatory reactions are induced. Skin troubles caused by these causes are not only aesthetic problems, but also substances produced during the inflammatory process may cause pigmentation of the skin and accelerate the breakdown of skin elastic fibers, thereby affecting the increase of skin wrinkles. It is known to lead to skin aging. Therefore, one of the areas of interest in cosmetics is how to delay skin aging. The final phenomena that appear in accordance with aging of the skin include wrinkle formation, skin elasticity reduction, aging spot formation, and the like, in particular, wrinkle formation is accepted as the most representative phenomenon.
피부의 노화는 크게 내인적 노화(intrinsic aging)와 외인적 노화(extrinsic aging)로 대별된다(Cosmetics & Toiletories, 111:31-37(1996)). 내인적 노화는 나이가 듦에 따라 피부의 생리적 기능이 점차 저하되어 자연적으로 나타나는 노화 현Skin aging is largely divided into intrinsic aging and extrinsic aging (Cosmetics & Toiletories, 111: 31-37 (1996)). Endogenous aging is a aging phenomenon that occurs naturally as the skin ages and the physiological function of the skin gradually decreases.
상으로 임상학적으로 탄력이 감소하고, 피부결이 거칠어지며, 깊은 주름이 생기며 색소가 침착되는 특징이 있다(Arch Dermatol., 130:87-95(1994)). 외인적 노화는 자외선, 활성 산소종(reactive oxygen species) 및 스트레스 등의 외인적 요인에 의해 발생하는 노화 현상을 말한다. 이러한 요인들에 의해 피부의 노화가 급속히 진행되며, 그 결과 피부 표면에 거친 주름이 생성되고 탄력이 현저히 감소하게 된다.(Physiology Of The Skin , Allured Publishing Corporation , Peter T. Pugliese.MD, p61 -72)It is clinically characterized by reduced elasticity, rough skin texture, deep wrinkles and pigmentation (Arch Dermatol., 130: 87-95 (1994)). Exogenous aging refers to the aging phenomenon caused by exogenous factors such as ultraviolet light, reactive oxygen species and stress. And by these factors rapidly progressing aging of the skin, resulting in wrinkles, rough skin surface is generated is significantly reduced elasticity. (Physiology Of The Skin , Allured Publishing Corporation, Peter T. Pugliese.MD, p61 -72 )
피부의 노화 기작을 규명하기 위한 여러 연구들이 진행되어 여러 가지 피부 노화의 원인들이 밝혀졌다. 피부가 온도의 변화, 습도의 저하 또는 바람 등에 의해 건조하게 되면 외부에 대한 방어벽으로서의 피부 생리 활성이 저하되어 노화가 촉진된다. 또한, 유해 활성산소종 또는 자유 라디칼에 피부가 노출되면 체내의 산화 작용에 의해 과산화 지질이 생성되고 피부를 구성하는 여러 단백질들의 변형을 유발하게 된다. 한편 피부 진피의 대부분(피부 전체 건조 중량의 약 70-80%)을 차지하는 피부의 주요 구조적 성분인 콜라겐과 엘라스틴은 자연적 또는 외부 자극에 의해 구조가 변성되거나 생합성량이 감소하게 되는데 이로 인해 피부 노화가 가속화된다.Various studies have been conducted to investigate the mechanism of aging of the skin, revealing various causes of skin aging. When the skin is dried by a change in temperature, a decrease in humidity or wind, the skin physiological activity as a protective barrier against the outside is lowered to promote aging. In addition, when the skin is exposed to harmful free radicals or free radicals, lipid peroxide is produced by oxidative action in the body and causes modification of various proteins constituting the skin. On the other hand, collagen and elastin, which are the major structural components of the skin that make up most of the dermis (about 70-80% of the total dry weight of the skin), are denatured or reduced in biosynthesis by natural or external stimuli, which accelerates skin aging. do.
피부의 구조에 따라 피부 노화 원인을 좀 더 구체적으로 살펴보면, 피부는 크게 표피와 진피로 나뉘는데, 표피에서는 각질 형성 세포의 turn-over의 감소로 각질층의 누적과 이로 인해 각질층의 두꺼워지고, 수분 함유 능력이 감소되고, 각질이 경화되어 주름이 발생하게 된다. In detail, the skin is divided into epidermis and dermis according to the structure of the skin. In the epidermis, the turnover of keratinocytes is reduced, the accumulation of the stratum corneum and the thickening of the stratum corneum and the water-containing ability This decreases and the keratin cures and wrinkles are generated.
또한, 표피와 진피의 경계부위는 표피세포 지지, 부착, 영양물질의 이동, 표피 분화의 조절 등에 관여하는데, 각종 노화 요인 특히, UV 에 인하여 콜라겐 IV, VII이 감소되어 표피, 진피 지지기능이 감소되고, 선별 투과 기능이 약화되어 해로운 성분이 쉽게 진피에 영향을 미치게 되어 주름이 생성된다. (Keene, J. Cell Biol., 104, p611 -621, 1987) In addition, the epidermal and dermal borders are involved in epidermal cell support, adhesion, transport of nutrients, and regulation of epidermal differentiation. As a result, the selective permeation function is weakened so that harmful components easily affect the dermis and wrinkles are generated. (Keene, J. Cell Biol., 104, p611 -621, 1987)
또한, 진피는 표피의 아래에 있는 결합조직으로 이루어지는 조직으로 표피 세포인 케라티노사이트처럼 치밀하게 채워져 있지 않고 세포외 공간이 많으며 세포외 간질(extracellular matrix)이라 불리는 거대 분자의 망상 구조에 의해 채워져 있다. 이 세포외 간질은 진피 내의 섬유아세포에서 만들어지며, 콜라겐, 엘라스틴 등의 섬유상 단백질과 히알루론산 등의 산성 뮤코다당이라 불리는 다당류로 이루어져 있다. 세포외 간질은 피부의 탄력성, 신진대사, 생기 등에 직접적으로 관여하고 있다. 좀 더 자세히 설명하면, 산성 무코다당은, 대량의 물을 이의 분자내에 유지하여 겔상을 나타내고, 이 겔내의 물이 영양분, 대사산물, 호르몬 등을 혈관으로부터 조직 중의 세포까지 침투시키는 작용을 담당하고 있다. 따라서, 세포 외 간질에 있어서의 산성 무코다당의 생산이 촉진되면, 피부가 싱싱하게 될 뿐만 아니라, 피 부의 신진 대사가 촉진되어, 피부 노화를 방지하는 것이 가능하게 된다. 또한, 섬유성 단백질은, 조직의 형태를 유지하거나, 피부에 탄성을 부여하는 등의 기능을 담당하고 있다. 따라서 세포외 간질에 있어서 섬유성 단백질의 생산이 촉진되면, 피부에 탄력을 주게 되어 주름 또는 잔주름이 억제된다. 이러한 세포외 간질을 생산하는 섬유아세포의 활성이 내적, 외적인 노화 요인, 특히, UV에 의해 저하되게 되면 콜라겐 생합성이 감소하고 변성된 엘라스틴이 증가하게 된다. 콜라겐과 신축성이 큰 엘라스틴 단백질은 섬유아세포에서 생성되는 주요 단백질로 피부 진피층에서 피부의 기계적 견고성, 조직의 결합력 및 탄력성 등에 관여한다(Journal of the american academy of dermatology, 21:610-613(1989)). 콜라겐은 연령이 증가할수록, 그리고 자외선에 노출이 많이 될수록 양적 감소를 보인다. 콜라겐은 형태와 구조적 특징에 따라서 분류되는데 이들 중에서, 가장 특징이 잘 알려진 것은 타입 I, II, III 그리고 IV이다. 콜라겐 타입 I과 III는 진피층의 세포간질의 구성성분을 이루고 콜라겐 타입 IV는 DEJ (Dermal Epidermal Junction)의 주요 구성물질이 된다. DEJ는 피부의 표피층과 진피층 사이에 위치하여 두 층간의 물질 투과와 수송을 조절해주며 인접한 피부세포의 분화를 조절하며 피부의 견고성을 유지시켜준다.이렇듯, 섬유아 세포의 감소 및 세포의 활성도 손상은 피부 노화 프로세스 중에 중요한 부분을 차지한다. In addition, the dermis is a tissue composed of connective tissue below the epidermis, which is not densely packed like the epidermal keratinocytes but has a lot of extracellular space and is filled by a network of macromolecules called extracellular matrix. . This extracellular epilepsy is made from fibroblasts in the dermis and consists of fibrous proteins such as collagen and elastin and polysaccharides called acidic mucopolysaccharides such as hyaluronic acid. Extracellular epilepsy is directly involved in skin elasticity, metabolism and vitality. In more detail, the acidic mucopolysaccharide retains a large amount of water in its molecule to form a gel, and water in the gel is responsible for penetrating nutrients, metabolites, and hormones from blood vessels to cells in tissues. . Therefore, when the production of acidic mucopolysaccharides in extracellular epilepsy is promoted, not only the skin is fresh but also the metabolism of the skin is promoted, and skin aging can be prevented. In addition, the fibrous protein is responsible for maintaining the shape of the tissue and imparting elasticity to the skin. Therefore, when the production of fibrous protein is promoted in extracellular epilepsy, elasticity is given to the skin and wrinkles or fine lines are suppressed. When the activity of fibroblasts producing such extracellular epilepsy is degraded by internal and external aging factors, particularly UV, collagen biosynthesis decreases and denatured elastin increases. Collagen and elastic elastin proteins are the major proteins produced by fibroblasts and are involved in the skin's mechanical firmness, tissue adhesion and elasticity in the dermal layer of the skin (Journal of the american academy of dermatology, 21: 610-613 (1989)). . Collagen decreases with age and with increasing exposure to ultraviolet light. Collagen is classified according to form and structural features, the most well known of which are Type I, II, III and IV. Collagen types I and III constitute the constituents of the cytoplasm of the dermis, and collagen type IV is the major component of DEJ (Dermal Epidermal Junction). DEJ is located between the epidermal and dermal layers of the skin to regulate the permeation and transport of materials between the two layers, to control the differentiation of adjacent skin cells and to maintain the firmness of the skin. Is an important part of the skin aging process.
이러한 피부노화를 억제시키거나 진행 속도를 완화시키기 위하여, 레티놀, 레티노이드, 비타민 C, 플라보노이드 및 토코페롤 등의 여러 가지 피부 보호 성분 이 함유된 화장료 또는 피부 보호제가 개발되고 있다. 그러나 이와 같은 화장료 또는 피부 보호제는 최종적인 제형에 있어서 역가가 떨어져 그 효능이 경미하고, 피부 자극이 심한 문제점을 지니고 있다.In order to suppress the skin aging or to slow the progression, cosmetics or skin protectants containing various skin protection ingredients such as retinol, retinoid, vitamin C, flavonoids and tocopherol have been developed. However, such cosmetics or skin protectors have a problem in that the potency is low in the final formulation, the efficacy is slight, and the skin irritation is severe.
최근 들어서는 이러한 원료들의 피부 자극 문제 때문에 보다 안전하고 피부에 자극이 없는 천연 식물성 원료를 이용한 화장품 개발이 많이 이루어지고 있다. 특히, 국내에서는 천연 한방 원료를 이용한 화장품을 많이 개발하고 있는데 이러한 이유는 천연 한방 원료들이 오래전부터 민간에서 사용되어 오면서 안전성, 유효성등이 이미 확보되어 있어 화장품 원료로 사용하는데 큰 문제점이 없는 것으로 인식되고 있기 때문이다.Recently, due to the skin irritation problem of these raw materials, the development of cosmetics using natural vegetable raw materials that are safer and have no skin irritation have been made. In particular, in Korea, we are developing a lot of cosmetics using natural herbal ingredients. This is because natural herbal ingredients have been used in private for a long time and safety and effectiveness have already been secured. Because there is.
이에 본 발명자들은 종래부터 생약으로 사용되어 오던 자연의 천연물을 대상으로 연구를 수행하였고, 그 결과 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향, 백강잠의 혼합 추출물과 인삼, 지황, 꿀 혼합추출물 및 행인, 과루근, 백봉령 혼합 추출물로 이루어진 생약 혼합물에 세포증식 및 대사 활성 증진, 프리 라디칼 소거, 콜라겐 생산촉진에 의한 피부 주름 개선과 피부 탄력 개선효과가 뛰어나다는 것을 발견하였다. Therefore, the present inventors conducted research on natural natural products that have been used as a herbal medicine in the past, and as a result, white paper, dongwain, cheongung, dongle, sessin, earthen root, caucus, bark skin, shinyi, gamsonghyang, Baekgangjam It is excellent in improving skin wrinkle and skin elasticity by enhancing cell proliferation and metabolic activity, free radical scavenging, and promoting collagen production in the herbal mixture consisting of mixed extract and ginseng, turmeric, honey mixed extract and algae, fruit root, Baekbongryeong mixed extract Found.
종래 선행특허들에 있어서, 백지의 경우 보습 및 미백용(한국 특허 공개 2006-92179), 노폐물 제거용(한국 특허 공개 2002-93655), 동과인의 경우 노폐물 제거용(한국 특허 공개 2002-93655), 둥글레의 경우 보습용(한국 특허 공개 1997- 32840), 토과근의 경우 보습용(한국 특허 공개 2002-93655), 감송향의 경우 보습 및 미백용(한국 특허 공개 2006-92179), 미백용(한국 특허 공개 2000-20728, 한국 특허 공개 2003-21811), 과루근의 경우 노폐물 제거용(한국 특허 공개 2002-93655), 미용(1995-7824)으로 사용된 예는 있으나 노화 방지용으로 사용된 예가 없었다. 뿐만 아니라 본 발명의 생약 성분인 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향, 백강잠과 인삼, 지황, 꿀, 행인, 과루근, 백봉령을 모두 함유하는 피부 노화 방지용 화장물 조성물에 대해서는 언급된 적이 없었다. In the prior patents, moisturizing and whitening in the case of white paper (Korean Patent Publication 2006-92179), for the removal of waste (Korean Patent Publication 2002-93655), for the removal of waste in the case of copper and wine (Korean Patent Publication 2002-93655) ), Moisturizing for Koreans (Korean Patent Publication No. 1997-32840), moisturizing for earthwork muscles (Korean Patent Publication 2002-93655), moisturizing and whitening (Korean Patent Publication 2006-92179), whitening (Korean Patent Publication No. 2000-20728, Korean Patent Publication No. 2003-21811), In case of fruiting roots, there are examples used for removing waste matter (Korean Patent Publication No. 2002-93655), beauty (1995-7824), but examples used for anti-aging There was no. In addition, the herbal ingredients of the present invention, white paper, ginkoin, cheongung, dongle, sessin, earthen root, doin, velvet skin, shinyi, saengsonghyang, baekgangjam and ginseng, jihwang, honey, almond, fruit root, Baekbongryeong There is no mention of a cosmetic composition for preventing skin aging.
이에 본 발명자들은 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 혼합 추출물(가감천금단)과 인삼, 지황 및 꿀로 이루어진 혼합추출물(가감경옥고)과 행인, 과루근 및 백봉령으로 이루어진 혼합 추출물(가감홍옥산)이 상술한 바와 같이 주름이 없는 생생한 피부를 유지하는데 있어 가장 중요한 역할을 담당하고 있는 세포외 간질을 생합성하는 섬유아 세포의 증식과 대사를 원활히 함은 물론, 생합성을 촉진하는 효과가 있으며 프리라디칼 저해능이 뛰어나서 주름, 잔주름, 피부의 거칠어짐 등으로 나타나는 피부 노화를 근본적으로 예방할 뿐만 아니라 안정성에도 문제가 없음을 발견하였다. 아울러, 세가지 혼합추출물을 혼합하였을 때 시너지 효과를 일으켜 피부 노화 예방 및 개선에 보다 탁월한 효과를 발휘함을 발견하여 본 발명을 완성하였다. Therefore, the inventors of the present invention is a mixed extract (gagamcheoncheon forbidden) consisting of white paper, dongguin, cheonggung, roundle, sessin, earthworm, doin, bark skin, shinyi, persimmon fragrance and baekgangjam and mixed extract consisting of ginseng, sulfur and honey And the proliferation of fibroblasts that biosynthesize extracellular epilepsy, which is the most important role in maintaining the skin without wrinkles as described above. In addition to smoothing metabolism, it has the effect of promoting biosynthesis and excellent free radical inhibiting ability, thereby fundamentally preventing skin aging caused by wrinkles, fine lines, rough skin, and the like, and found no problem in stability. In addition, the synergistic effect of the three mixed extracts were found to exert a more excellent effect in preventing and improving skin aging to complete the present invention.
본 발명의 목적은 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 생약 추출 혼합물을 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공하고자 하는 것이다. An object of the present invention is to provide a skin anti-aging cosmetic composition comprising a herbal extract mixture consisting of white paper, gingin, cheongung, dongle, sessin, earthworm, cauliflower, bark skin, shinyi, saengyanghyang and baekjap as an active ingredient. .
본 발명의 목적은 본 발명은 인삼, 지황 및 꿀로 이루어진 생약 추출 혼합물을 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공하고자 하는 것이다. An object of the present invention is to provide a cosmetic composition for preventing skin aging, comprising the herbal extract mixture consisting of ginseng, sulfur and honey.
본 발명의 목적은 본 발명은 행인, 과루근 및 백봉령으로 이루어진 생약 추출 혼합물을 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공하고자 하는 것이다.It is an object of the present invention to provide a cosmetic composition for preventing skin aging, comprising a herbal extract mixture consisting of algae, fruit root and Baekbongnyeong as an active ingredient.
본 발명의 목적은 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 생약 추출 혼합물과 인삼, 지황 및 꿀로 이루어진 생약 추출 혼합물과 행인, 과루근 및 백봉령으로 이루어진 생약 추출 혼합물 모두를 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공하고자 하는 것이다. An object of the present invention is a herb extract mixture consisting of white paper, Dongguin, Cheongung, roundle, sessin, earthworm, Doin, bark skin, Shinyi, saengsonghyang and Baekjajam and herbal extract mixture consisting of ginseng, turmeric and honey, and passersby And it is to provide a cosmetic composition for preventing skin aging comprising all of the herbal extract mixture consisting of Baekbongryeong as an active ingredient.
본 발명의 목적은 세포증식 및 대사 활성 효과를 가짐을 특징으로 하는 피부 노화 방지용 화장료 조성물을 제공하고자 하는 것이다. An object of the present invention is to provide a cosmetic composition for preventing skin aging, characterized in that it has a cell proliferation and metabolic activity effect.
본 발명의 목적은 프리 라디칼 소거효과를 가짐을 특징으로 하는 피부 노화 방지용 화장료 조성물을 제공하고자 하는 것이다. An object of the present invention is to provide a cosmetic composition for preventing skin aging, characterized in that it has a free radical scavenging effect.
본 발명의 목적은 콜라겐 생산촉진 효과를 가짐을 특징으로 하는 피부 노화 방지용 화장료 조성물을 제공하고자 하는 것이다. An object of the present invention is to provide a cosmetic composition for preventing skin aging, characterized in that it has a collagen production promoting effect.
본 발명의 목적은 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 생약 추출 혼합물과 인삼, 지황 및 꿀로 이루어진 생약 추출 혼합물과 행인, 과루근 및 백봉령으로 이루어진 생약 추출 혼합물을 유효 성분으로 하는 피부 노화 방지용 화장료 조성물의 제조방법을 제공하고자 하는 것이다. An object of the present invention is a herb extract mixture consisting of white paper, Dongguin, Cheongung, roundle, sessin, earthworm, Doin, bark skin, Shinyi, saengsonghyang and Baekjajam and herbal extract mixture consisting of ginseng, turmeric and honey, and passersby And to provide a method for producing a skin anti-aging cosmetic composition comprising the herbal extract mixture consisting of Baekbongryeong as an active ingredient.
본 발명의 한 양태에 따르면, 본 발명은 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 생약 추출 혼합물을 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공한다. According to an aspect of the present invention, the present invention provides a skin anti-aging cosmetic composition comprising an herbal extract mixture consisting of white paper, gingiwine, celestial organ, roundle, sesins, earthworm muscle, cabbage, bark skin, shinyi, saengsonghyang and napja To provide a composition.
본 발명의 다른 양태에 따르면, 본 발명은 인삼, 지황 및 꿀로 이루어진 생약 추출 혼합물을 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공한다. According to another aspect of the present invention, the present invention provides a cosmetic composition for preventing skin aging, comprising as an active ingredient a herbal extract mixture consisting of ginseng, sulfur and honey.
본 발명의 다른 양태에 따르면, 본 발명은 행인, 과루근 및 백봉령으로 이루어진 생약 추출 혼합물을 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공한다. According to another aspect of the present invention, the present invention provides a cosmetic composition for preventing skin aging, comprising as an active ingredient a herbal extract mixture consisting of algae, fruit roots and Baekbongnyeong.
본 발명의 다른 양태에 따르면, 본 발명은 상기 세 가지 생약 추출 혼합물 모두를 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공한다. According to another aspect of the present invention, the present invention provides a cosmetic composition for preventing skin aging comprising all three herbal extract mixtures as an active ingredient.
즉, 본 발명은 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 생약 추출 혼합물과 인삼, 지황 및 꿀로 이루어진 생약 추출 혼합물과 행인, 과루근 및 백봉령으로 이루어진 생약 추출 혼합물 모두를 유효 성분으로 하는 피부 노화 방지용 화장료 조성물을 제공한다. That is, the present invention is a herbal medicine extract mixture consisting of white paper, dongguin, cheonggung, roundle, sessin, earthworm, doin, bark skin, sinyi, saengsonghyang and baekgangjam and herbal extract mixture consisting of ginseng, turmeric and honey, and passersby And it provides a cosmetic composition for preventing skin aging comprising all of the herbal extract mixture consisting of Baekbongryeong as an active ingredient.
본 발명은 상기 세 가지 생약 추출 혼합 추출물 모두를 동시에 적용함으로써 시너지 효과를 보인다. 본 발명에서의 용어 "시너지"라 함은 서로 다른 생약 추출 혼합물 각각이 가지는 효과를 넘어서, 각각의 효과를 합한 것 이상의 효과를 내는 것으로 전체적 효과에 기여하는 각 기능의 공동작용이나 협동을 의미한다. 본 발명의 실험예 4 내지 7에서도 보여주고 있듯이, 생약 추출 혼합물을 각각 적용한 것에 비하여 세가지 생약 추출 혼합물을 동시에 적용하였을 때, 세포 대사 활성, 세포 증식, 콜라겐 합성 면에서 각각의 효과를 합한 것 이상의 피부 노화 방지, 개선 및 치료 효과를 나타낸다. The present invention shows a synergistic effect by applying all three herbal extracts mixed extract at the same time. The term "synergy" in the present invention refers to the synergy or cooperation of each function that contributes to the overall effect by producing more than the combined effect of each of the different herbal extract mixtures. As shown in Experimental Examples 4 to 7, according to the present invention, when three herbal extract mixtures were simultaneously applied compared to the respective herbal extract mixtures, the skin metabolism activity, cell proliferation, collagen synthesis and more than the combined effects of each skin Anti-aging, improvement and therapeutic effect.
본 발명에서 사용된 천궁(Cnidium officinale Makino)은 다년생 초본으로 높이가 40-70 cm이고, 식물체에 향기가 나는 특징을 가지고 있다. 상기 천궁의 뿌리는 불규칙한 결절상의 덩어리로서 직경이 2-7 ㎝이며 표면은 황갈색으로 거친 주름이 있고 평행으로 융기한 윤절이 여러 개 있으며 정상부에는 오목한 원형의 줄기 흔적이 있다. 그 단면은 황백색 혹은 회황색인데 황갈색의 유실이 산재해 있고 형성층은 물결 모양의 황문을 이룬다. 천궁의 뿌리는 한방에서 보혈, 강장, 진정 및 진통 등을 목표로 냉증, 빈혈 및 월경 장애 등 각종 부인병 질환에 쓰이고 있다. 천궁은 멜라노사이트 자극 호르몬의 활성을 저해하며, 이러한 특성은 결과적으로 티로시나아제의 생성을 억제하여 멜라닌 생성을 억제함으로써 색소 침착을 방지하며 미백 효과를 나타낸다. 미나리과의 여러해살이풀로 중국이 원산이며 약용 작물로 재배한다. 높이 30 ~60cm이며, 성분으로는 크니딜라이드(cnidilide), 리구스틸라이드(ligustilide), 네오크니딜라이드 (neocnidilide), 부틸프탈라이드 (butylphthalide), 세다노닉산(sedanonic acid) 등이 알려져 있다. 천궁은 한방에서는 그 뿌리줄기를 건조하여 사용하고, 자궁 진정작용과 혈압조절작용, 항균작용, 피부사상균에 대한 억제 작용, 두통, 빈혈, 불임, 월경불순, 냉증 등의 부인병에 사용하였다. 민간에서 좀 예방을 위해 옷장에 넣어두었다(정보섭, 신민교, 향약 대사전, pp418, 1998).Cnidium officinale Makino used in the present invention is a perennial herb, 40-70 cm in height, and has the characteristic of smelling plants. The root of the uterus is an irregular nodular lump, 2-7 cm in diameter, yellowish brown with coarse wrinkles, several parallel raised bumps, and a top of the concave circular stem trace. Its cross section is yellowish white or greyish yellow with scattered yellowish brown oil and the formation layer is wavy yellowish gate. The root of Cheongung is used for various gynecological diseases such as cold syndrome, anemia and dysmenorrhea disorder with the aim of blood, tonic, soothing and pain relief in oriental medicine. The uterus inhibits the activity of melanocyte stimulating hormones, which in turn inhibits the production of tyrosinase, inhibits melanin production, thereby preventing pigmentation and exerts a whitening effect. It is a perennial plant of the family Apiaceae, native to China and grown as a medicinal crop. Its height is 30-60 cm and its components are known as cnidilide, ligustilide, neocnidilide, butylphthalide and sedanonic acid. Cheonggung was used to dry the root stem in oriental medicine and used for gynecological diseases such as uterine sedation, blood pressure control, antibacterial action, inhibitory effect on dermatophytes, headache, anemia, infertility, dysmenorrhea and coldness. It was put in the closet for some prevention in the private sector (Information, Shin Min-kyo, Ambassador of Yakyang, pp418, 1998).
본 발명에서 사용된 신이(Magnolia denudata Desrousseaux)는 낙엽성 관목으로 중국 남방 각지의 정원에서 재배하며 야생은 적다. 목련과(Magnoliaceae)에 속하며 봄철 꽃봉오리가 벌어지기 전에 따서 햇볕에 말려 이용한다. 기원식물은 Magnolia denudata로 이것 외에도 한국 생약 규격집에는 magnolia kobus, Magnolia salicifolia Maxim.이 있으며 중국약전에는 Magnolia biondii, Magnolia sprengeri, Magnolia liliflora, Magnolia faragesii로 규정되어 있다. 신이는 전 통적으로 풍으로 속골이 아픈 것을 낫게 하며 얼굴의 주근깨를 없애고 코가 메는 것, 콧물이 흐르는 것 등을 낫게 하며 눈을 밝게 하며 수염과 머리털을 나게 한다고 알려져 있다(본초강목). 또한 신이와 관련되어서 피부 미백효과 및 항염 효과를 가지는 화장료 조성물(일본 특개평 5-320034), 피부병치료제(일본 특개평 5-246874), 소취제(일본 특개평 5-212099) 등의 연구가 보고되어 있으나 본 발명과는 완전히 구별된다. 기존의 신이 성분 동정 연구에 의하면 마그놀롤(Magnolol), 시린긴(Syringin), 호노키올(Honokiol), 유게놀(Eugenol), 티라민(Thyramine) 등의 물질이 보고되어 있다.As used in the present invention (Magnolia denudata Desrousseaux) is a deciduous shrub cultivated in gardens in southern China, the wild is less. It belongs to Magnoliaceae, and it is picked up and dried in the sun before spring buds open. The plant of origin is Magnolia denudata. Besides, the Korean herbal medicine standard contains magnolia kobus, Magnolia salicifolia Maxim.The Chinese Pharmacopoeia defines Magnolia biondii, Magnolia sprengeri, Magnolia liliflora, Magnolia faragesii. Shin is traditionally known to relieve sore bones with wind, to get rid of freckles on the face, to heal noses and runny noses, to brighten the eyes, and to produce beards and hair (primary wood). In addition, research has been reported on cosmetic compositions (Japanese Patent Laid-Open Publication No. 5-320034), skin disease treatment agents (Japanese Patent Laid-Open Publication No. 5-246874), and deodorant (Japanese Patent Laid-Open Publication No. 5-212099) having a skin whitening effect and an anti-inflammatory effect in association with sinusitis. However, it is completely distinct from the present invention. Existing god-identification studies have reported substances such as Magnolol, Syringin, Honokiol, Eugenol, and Thyramine.
본 발명에서 사용된 백지(Angelica Dahuricae Radix)는 산형과(Umbelliferae) 식물인 구릿대를 기원으로 하며 다년생 초본으로 풀이 무성한 저습지나 관목 숲 또는 강가에서 자란다. 가을철에 근부를 채취하여 햇볕에 말려 사용한다. 기존의 성분 동정 연구에 의하면 쿠마린(Cumarins), 비악-안겔리신(Byak-angelicin), 오신(Oscine), 강초톡신(Xangthotoxin), (-)-노카데켄네틴((-)-Nokadekenetin)등의 물질이 알려져 있다. 백지는 전통적으로 열이나 풍으로 머리가 아픈 것을 치료한다고 알려져 있으며 또한 풍증으로 어지러운 것을 낫게 하는데 알약을 만들어 복용한다(본초강목). 한방에서는 진통, 지혈, 진정약으로 사용한다. 백지와 관련된 연구를 살펴보면 피지분비 촉진에 의한 피부염 치료(일본 특개평 9-176030), 인체 안정성이 뛰어난 발모 억제제(일본 특개평 10-139639), 온욕 효과를 높인 입욕제(일본 특개평 06-206814) 등이 알려져 있고, 동의보감과 신농본초경에 상기 백지를 고약과 분으로 만들어 얼굴에 바르면 따뜻한 기운을 얼굴 피부로 보내 혈액순환을 촉진하여 안색을 기름지게 윤택하게 하며, 얼굴에 기미와 주근깨, 흉터를 없앤다고 기록하고 있다.The white paper (Angelica Dahuricae Radix) used in the present invention originates from a copper clam, which is a umbelliferae plant, and is a perennial herb and grows in grassy wetlands or shrubs or rivers. Collect roots in autumn and dry them in the sun. Existing ingredient identification studies show that Kumarins, Byak-angelicin, Oscine, Xangthotoxin, (-)-Nokadekenetin, etc. The substance is known. White paper is traditionally known to cure head soreness due to heat or wind. Herbal medicine, pain relief, hemostatics, used as a sedative. In studies related to white paper, the treatment of dermatitis by promoting sebum secretion (Japanese Patent Laid-Open No. 9-176030), hair growth inhibitor with excellent human stability (Japanese Patent Laid-Open No. 10-139639), and bathing agents with increased warming effect (Japanese Patent Laid-Open No. 06-206814) It is known that the white paper is made of plasters and powders in Dongbobogam and Shinnong-bonbyeon, and when applied to the face, it sends warm energy to the facial skin to promote blood circulation, oiling the complexion, and removing blemishes, freckles, and scars on the face. Doing.
본 발명에서 사용된 감송향(Nardostachys chinensis Batal)은 다년생 초본으로 고산의 초지나 초원의 도랑가에서 자라며, 봄과 가을에 채취하여 지하경이나 뿌리를 이용한다. 감송향은 마타리과(valerianaceae)에 속하며 우리나라에서의 기원식물은 Nardostachysis chinensis Batal.로 중국에서는 이것 이외에도 Nardostachysis jatamansi로 규정되어 있다. 감송향은 전통적으로 완복창통, 구토, 식욕부진, 치통 등의 각종 한방약재로 사용되어 왔다(참조: 본초강목). 또한 감송향과 관련되어서 피부 건조개선 및 아름다운 피부유지를 위한 화장료 조성물(참조: 일본 특개평 8-259423), 피부병 치료제(참조: 일본 특개평 5-246874) 등의 연구가 보고되어 있다. 그러나, 라디컬 소거 효과에 대해서는 보고되지 않았다. 기존의 감송향 성분 동정연구에 의하면 에틸-β-D-글루코피라노사이드, 나르도스타친(Nardostachin),칸숀(Kanshone), 나르도퓨란(Nardofuran) 등의 화합물이 보고되어 있다.The persimmon scent (Nardostachys chinensis Batal) used in the present invention is a perennial herb and grows in alpine pastures or grassland trenches, and is collected in spring and autumn to use underground diameters or roots. Persimmon is a member of the family Valerianaceae. The plant of origin in Korea is Nardostachysis chinensis Batal. In addition to this, it is defined as Nardostachysis jatamansi in China. Persimmon scent has traditionally been used in various herbal medicines such as bloating pain, vomiting, loss of appetite, and toothache. In addition, researches on cosmetic compositions (see Japanese Patent Application Laid-Open No. 8-259423) and dermatological treatments (Japanese Patent Application Laid-open No. 5-246874) have been reported in connection with sweet odor. However, no reports of radical scavenging effects have been reported. Existing research on the sensitizing component has reported compounds such as ethyl-β-D-glucopyranoside, Narstastachin, Kanshone, and Nardofuran.
본 발명에서 사용된 인삼(Panax ginseng C. A. Mey.)은 다년성 초본으로서, 진세노사이드(Ginsenoside)류, 다마나란(Damanarane), 올레노익산(Oleanolic acid), 파낙시놀(Panaxynol) 등의 성분을 다량함유하고 있어 피부미용의 측면에서 볼 때 신진대사촉진, 피부노화방지, 이상세포억제, 혈액순환촉진 등의 효과를 나타낸다. 원기 부족으로 인한 신체허약, 권태, 피로, 땀이 많은 증상, 비위 기능의 감퇴로 인해 나타나는 식욕부진, 구토, 설사에 활용된다. 폐 기능의 약화로 인해 호흡이 가쁜 경우에도 활용되며, 또한 진액을 생성있어서 진액 손상으로 기운이 없으면서 갈증이 있는 경우 및 소갈증에 널리 쓰인다. 안신(安神)작용이 있어서 꿈이 많고 잠을 이루지 못하면서 가슴이 뒤고 잘 놀며, 정신력을 증강시키고 사고력과 영적활동을 높인다. 기운이 허약해서 혈허 증상을 일으키는 사람에게는 기혈(氣血)을 보해 준다. 그 밖에도 신기능 허약으로 인하여 음위증(陰 症:발기부전)을 일으킬 때 강장효과가 있다.Ginseng (Panax ginseng CA Mey.) Used in the present invention is a perennial herb, a component such as Ginsenosides, Damanarane, Oleanolic acid, Panaxynol, and the like. In terms of skin beauty, it has effects of promoting metabolism, preventing skin aging, inhibiting abnormal cells, and promoting blood circulation. It is used for anorexia, vomiting and diarrhea caused by physical weakness, boredom, fatigue, sweaty symptoms, and loss of nasal function due to lack of energy. It is also used in cases of shortness of breath due to weakened lung function, and is also used for thirst and thirst without energy due to damage to the fluid due to the production of essence. With the action of anxiety, many dreams and sleeplessness, do not sleep, play well, strengthen the mental power, enhance the thinking and spiritual activities. If the energy is weak, causing symptoms of blood loss will give blood (氣血). In addition, due to renal function weakness is a tonic effect (음 症: erectile dysfunction) when the tonic effect.
본 발명에서 사용된 백복령(Poria cocas Wolf.)은 담자균류 민주름목 구멍장이버섯과의 버섯으로서 옛날부터 한방 재료로 이용되어 온 약용버섯이다. 약용으로 하는 것은 이 버섯이 땅 속의 소나무 뿌리에 만드는 균핵이며, 자실체는 균핵이 지표에 노출되었을 때 균핵의 표면에 드물게 형성된다. 균핵은 지름 10∼30㎝의 감자모양 또는 타원형 덩어리로, 표면은 암갈색이고, 주름이 많은 단단한 껍질로 덮여 있다. 육질(肉質)은 반쯤 마른 치즈와 비슷하고, 빛깔이 희다. 조직을 현미경으로 보면, 균사 조각에 섞여 광선을 심하게 굴절시키는 과립체(顆粒體)를 많이 볼 수가 있다. 이것은 균사의 변형물로, 요오드화칼륨용액에서 짙은 적갈색으로 변색되는 덱스트린반응을 나타낸다. 복령의 자실체는 균핵 위에 평평하게 퍼지고, 깊이 2∼20㎜, 지름 0.5∼2㎜의 관공(管孔)이 표면에 배열되어 있을 뿐, 버섯모양을 나타내 지 않으며, 색은 거의 흰색이다. 이뇨제·진정제·강장제로서, 부종(浮腫)·정신불안·동계(動悸)·소화불량 등의 치료에 사용된다. 또한, 피부 미용측면에서 해독작용, 주근깨예방, 피부보호(안정)의 효과가 있으며, 또 최근에는 함유성분의 하나로 다당류인 파키만에 항종양성작용(抗腫瘍性作用)이 있다는 발표도 있어, 약용효과가 한층 기대되고 있다.The baekbokyeong (Poria cocas Wolf.) Used in the present invention is a medicinal mushroom that has been used as a herbal material since ancient times as a mushroom of the fungus fungi Democracy. Medicinal is the fungus that this mushroom makes on pine roots in the ground, and fruiting bodies rarely form on the surface of the fungus when it is exposed to the surface. The bacterium is a potato or oval lump with a diameter of 10-30 cm, the surface is dark brown, and is covered with a hard wrinkled shell. Meat is similar to semi-dried cheese and is white in color. When the tissue is viewed under a microscope, many granules are mixed into the mycelium pieces and severely refract light rays. This is a variation of mycelium, which exhibits a dextrin reaction that changes color to dark reddish brown in potassium iodide solution. The fruiting body of Bokryeong spreads flat on the fungal nucleus, having only 2 to 20 mm of depth and 0.5 to 2 mm of pores arranged on the surface, showing no mushrooms, and almost white in color. Diuretics, soothing agents, tonics, used for the treatment of edema, mental anxiety, palpitations, dyspepsia. In addition, it has detoxification effect, prevents freckles, and protects the skin in terms of beauty of skin, and recently, there is an antitumor effect on pakiman, a polysaccharide as one of its ingredients. The effect is expected more.
본 발명에서 사용된 천궁(Cnidium officinale Makino)은 혈관확장 작용을 한다고 하며 항염증, 해열, 진통치료 작용 등이 보고되고 있으며 한방에서 보혈, 강장, 진정, 진통치료 등을 목적으로 사용되고 있다.Cnidium officinale Makino used in the present invention is said to have an effect of vasodilation, anti-inflammatory, antipyretic, analgesic treatment, and the like has been used for the purpose of the treatment of blood, tonic, sedation, analgesic, etc. in Oriental medicine.
본 발명에서 사용된 동과인(Benincase hispida cogniaux)은 일명 지지이며 덩굴에 열매가 맺어 처음에는 청옥색이고 서리를 맞으면 분을 바른 것 같이 희어지기 때무에 백동과라고도 한다. 기부(肌膚)를 두텁게 하고 얼굴색을 아름답게 하며 검은 주근깨를 없애니 기름을 만들어 얼굴에 바르면 좋다.Benincase hispida cogniaux, used in the present invention, is also known as the Baekdongdae because it is a support and bears fruit on the vines and is initially turquoise and whitens as if it is frosted. Thicken the base, make the face beautiful, and remove the black freckles.
본 발명에서 사용된 행인(Prunus armeniaca L.)은 기미를 없애주고, 만청자는 죽은깨를 없애주고 주름진 살을 펴지게 한다. Prunus armeniaca L. used in the present invention eliminates the appearance of blemishes, and the celadon removes dead sesame seeds and spreads wrinkled flesh.
본 발명에서 사용된 꿀은 꿀벌이 여러 식물의 꽃으로부터 수집한 화밀과 화분을 그들의 식량으로 전환하여 저장한 것으로, 2개의 단당류, 즉 글루코오 스(glucose)와 프룩토오스(fructose), 탄수화물, 무기질, 식물성 색소, 효소 및 화분 등을 함유하고 있다. 꿀의 성분 중 80% 이상은 글루코오스(glucose), 프룩토오스(fructose) 등의 단당류이다. 이 성분은 흡습성이 매우 뛰어나 피부에서 수분막을 형성하여 지속적인 보습효과를 가진다. 꿀 추출물은 이러한 성분이 다량 포함되어 있어 강력한 보습효과를 가진다.The honey used in the present invention is stored by converting the nectar and pollen collected from the flowers of various plants into their food, two monosaccharides, glucose and fructose, carbohydrate, It contains minerals, vegetable pigments, enzymes and pollen. More than 80% of honey's components are monosaccharides such as glucose and fructose. This ingredient has excellent hygroscopicity and forms a moisture film on the skin, which has a continuous moisturizing effect. Honey extract contains a large amount of these ingredients has a strong moisturizing effect.
본 발명에서 사용된 둥글레(Polygonatum odoratum(MILLER) var. pluriflorum Ohwi)는 외떡잎식물 백합목 백합과의 여러해살이풀로 이명으로 맥도둥굴레, 애기둥굴레, 좀둥굴레, 제주둥굴레 등이 있으며 약재명은 옥죽이다. 산과 들에서 자란다. 굵은 육질의 뿌리줄기는 옆으로 벋고 줄기는 6개의 능각(稜角)이 있으며 끝이 비스듬히 처진다. 높이는 30∼60cm이다. 잎은 어긋나고 한쪽으로 치우쳐서 퍼진다. 길이 5∼10cm, 나비 2∼5cm로 긴 타원형이고 잎자루가 없다. 6∼7월에 길이 15∼20mm의 녹색빛을 띤 흰색 꽃이 1∼2개씩 잎겨드랑이에 달리며, 작은꽃대는 밑부분에서 서로 합쳐진다. 수술은 6개이고 통부(筒部) 위쪽에 붙으며 수술대에 잔 돌기가 있다. 꽃밥은 길이 4mm로서 수술대의 길이와 거의 같다. 열매는 장과로 둥글고 9∼10월에 검게 익는다. 봄철에 어린 잎과 뿌리줄기를 식용한다. 생약의 위유는 뿌리줄기를 건조시킨 것이며, 한방에서는 뿌리줄기를 번갈·당뇨병·심장쇠약 등의 치료에 사용한다. 한국·일본·중국에 분포한다. 잎 뒷면에 유리조각 같은 돌기가 있고 꽃의 길이가 2∼2.5cm인 것을 산둥굴레(var. thunbergii), 잎 뒷면 맥 위에 잔 돌기가 많고 꽃이 1∼4개씩 달리는 것을 큰둥굴레(var. maximowiczii), 잎은 길이 16cm, 나비 5cm 정도이고 꽃이 4개씩 달리는 것을 맥도둥굴레(P. koreanum), 전체가 크고 잎 뒷면에 털이 있으며 꽃이 2∼5개씩 달리는 것을 왕둥굴레(P. robustum)라고 한다.Polygonnatum odoratum (MILLER) var. Pluriflorum Ohwi used in the present invention is a perennial herb of a monocotyledonous lily of the genus Liliumaceae. It grows in mountains and fields. The coarse fleshy rhizome is sideways and the stem has six ridges and the tip is slanted obliquely. The height is 30-60cm. The leaves are shifted and spread to one side. 5-10cm long, 2-5cm long, oval, without petioles. In June-July, 1 ~ 2 greenish white flowers, 15 ~ 20mm long, hang on the axilla, and the peduncles merge with each other at the bottom. There are 6 stamens, attached to the upper part of the tube, and there are small projections on the operating table. Anther is 4mm long and almost the same length as operating table. Fruits are round with berry and ripen black from September to October. Eat young leaves and rhizomes in spring. The crude oil of the herbal medicine is dried root stems, and in one shot, the root stems are used for the treatment of alternation, diabetes and heart failure. It is distributed in Korea, Japan, and China. On the back of the leaf, there are glass-like protrusions and flowers are 2 ~ 2.5cm in length, var. Thunbergii, and on the veins on the back of the leaf, there are many bumps, and 1 ~ 4 flowers are running on the leaf, var. Maximowiczii. , The leaves are 16cm long, 5cm butterfly, and 4 flowers are running each. P. koreanum, the whole is large and hairy on the back, and 2-5 flowers are called P. robustum.
본 발명에서 사용된 과루근(Prunus armeniaca L.)은 하늘타리뿌리라고도 하는 것으로, 일명 천화분(千花粉), 우명(又名), 천과(天瓜)라고도 하며 손과 얼굴의 주름을 없애며 토혈, 사혈, 적백리를 치료하는데 쓴다.As used in the present invention, Prunus armeniaca L. is also referred to as sky root roots, also known as cheonhwabun (千 花粉), stigma (천 名), cheonggwa (天 瓜) and eliminates wrinkles on hands and face, hemorrhage, Used to treat red blood, red Baekli.
본 발명에서 사용된 토과근(Thladiantha dubia Bunge)은 얼굴빛을 곱고 광택나게 하는 것이며, 행인은 기미를 없애준다. As used in the present invention (Thladiantha dubia Bunge) is to multiply and brighten the face, passerby eliminates blemishes.
본 발명에서 사용된 도인(Prunus persica)은 장미과(Rosaceae) 갈잎큰키나무 북숭아나무(Prunus persica (L.) B.)의 종자로 에물신(emulsion), 아미그달린(amygdalin), 리놀렌산(linolenic acid) 등이 함유되어 있다. 7 ~ 8월경 복숭아가 익었을 때 종자를 채집하여 단단한 씨껍질[種皮]을 깨고서 속에 들어 있는 자인을 꺼내어 주로 한약재로 쓴다. 계란모양을 한 편압(扁壓)된 작은 덩어리로서, 크기는 길이 1.2 ~ 2.0 cm, 너비 0.6 ~ 1.2 cm, 두께 0.3 ~ 0.7 cm이며, 적갈색의 얇은 껍질에 싸여 있고 그 속은 희다. 맛은 약간 쓰고 물을 가해 부술때는 벤즈알데히드의 방향(芳香)을 발산한다. 도인은 한방에서는 악혈이 체내에 있을 때 생리통, 무월경, 산후의 복통 등에 사용되고 진통, 소염, 해독, 완화제로 타박상, 삔데, 내 출혈 등에 사용되고 있으며, 민간에서는 생선을 먹고 중독되었을 때 복숭아를 먹으면 해독이 되고, 기침을 멈추게 하는 효능이 있는 것으로 알려져 있다. 이것이 포함되는 한방 처방에는 도핵승기탕 (桃核承氣湯), 대황모란피탕 (大黃牡丹皮湯), 계지복령환(桂枝茯笭丸) 등이 있다.Prunus persica used in the present invention is a seed of Rosaceae larch, Prunus persica (L.) B., emulsion, amygdalin, linolenic acid Etc. are contained. When the peach ripens around July-August, the seeds are collected, the hard seed husks are broken, and the vines are taken out and used mainly as herbal medicines. It is an egg-shaped one-piece small lump, 1.2-2.0 cm long, 0.6-1.2 cm wide, 0.3-0.7 cm thick, wrapped in a reddish brown thin shell, and white inside. The taste is slightly bitter and water is added to smash the fragrance of benzaldehyde. Doin is used for menstrual pain, amenorrhea and postpartum abdominal pain when the bleeding is in the body. It is used for pain, anti-inflammatory, detoxification, and as a relieving agent. It is known to have an effect of stopping a cough. Herbal prescriptions that include this include Dokukseunggi-tang (桃核 承 氣 湯), Rhubarb Moranpitang (大黃 牡丹皮 湯), Kejijibokyeonghwan (桂枝 茯 笭 丸) and the like.
본 발명에서 사용된 목단피 (Paeonia moutan Sims, P.subfruticosa Makino)는 중국 서부 원산이며 신라시대 선덕여왕의 기록으로 미루어 중국에서 도입된 귀화식물로 추측된다. 내한성이 강하여 함경북도를 제외한 전국에 분포하지만, 충북 단양군, 제원군과 전남 화순군에서 많이 재배되고 있다. 다년생 낙엽관목으로 높이는 1 ~ 1.5 m이다. 잎은 어긋나고, 2 회 삼출복엽이며 난형 또는 광란형이고 정생하는 소엽은 항상 셋으로 갈라지며, 측생하는 소엽도 장상으로 3 열한다. 꽃은 단생하고 크기가 크며, 꽃받침잎은 5 장이고, 꽃잎은 5 장 혹은 더 많으며 재배품종의 대부분은 겹꽃이 있고 변이가 많으며 장미색을 비롯하여 홍, 자, 백색 모두 있다. 수술은 여러 개이고 수술대는 홍색이며, 암술은 2 ~ 5개로 암술머리는 엽상이고 화반은 술잔모양이다. 외면은 암갈색~암적색이고, 가로로 작은 타원형의 곁뿌리 자국이 있으며, 세로주름이 있다. 내면은 담회갈색~암적색이고 편평하며, 파절면은 거칠고 백~담홍색을 띤 분말성이다. 특이한 냄새가 나기 때문에 용이하게 식별 할 수 있으며, 맛은 약간 맵고 쓰다. 안쪽 면 및 꺽인 면에 백색의 결정(paeonol)이 붙어 있고 신선한 향기가 강하게 나는 것일수록 좋은 상품이다. 모란과의 관목으로 각지에서 꽃 보기나 약초로 심는다. 가을에 뿌리를 캐서 목부를 빼버리고 볕에 말 린다. 뿌리껍질과 목심에는 페오놀 배당체인 페오노시드, 페오놀리드, 페오니플로린, 안식향산, 페오놀 등이 있다. 진정 진경약으로 자율신경부조에 쓰이며, 해열, 진통, 항염제로 쓰이며, 월경불순, 허리아픔 관절통 등에 쓰인다. 목단피와 복숭아씨(도인)를 함께 쓰면 항염 작용과 혈액순화개선 효과가 높아진다. 모란과(Paeoniaceae) 여러해살이풀 모란(Paeonia suffruticosa A.)의 뿌리껍질로 페오놀(paeonol)과 그 배당체인 페오노시드(paeonoside), 페오놀리드(paeonolide), 페오니플로린(paeoniflorin) 등이 함유되어 있다. 이는 부인약의 필수약재로서, 진정작용, 열내림작용, 아픔멎이작용, 항염작용 및 피멎이작용을 하며 혈압강하작용이 보고된 바 있다. 목단피는 도인과 병행 사용될 때 소염효과와 혈액순환개선의 효과가 보여주는 것으로 알려져 있다. 한편, 화장료와 관련된 목단피의 효능은 소염작용에 의한 종기치료효과, 티로시네이즈활성 저해효과가 있으며, 혈액순환 촉진과 항염작용 및 수렴작용으로 피부노화를 예방하는 효능이 알려져 있다. Peony (Paeonia moutan Sims, P.subfruticosa Makino) used in the present invention is native to western China and is believed to be a naturalized plant introduced in China due to the records of Queen Seondeok in the Silla period. It has strong cold resistance and is distributed throughout the country except North Hamgyong, but it is cultivated in Danyang-gun, Jewon-gun, and Hwasun-gun, Jeonnam. Perennial deciduous shrub, 1 ~ 1.5 m high. Leaves alternate, two-time exudates, egg-shaped or frenzied, and degenerative lobules are always divided into three, and lateral lobes are arranged in three rows. Flowers are single and large in size, with 5 sepals, 5 or more petals, and most of the cultivars are double-flowered, variegated, rose, red, purple, and white. There are several stamens, the operating table is red, pistil is 2 to 5, pistil is lobed, and the flower bed is cup-shaped. The outer surface is dark brown to dark red, and there are small oval side root marks on the side, and there are vertical wrinkles. The inner side is light brown to dark red and flat. The fracture surface is rough and white to pink powdery. It has an unusual smell, so it can be easily identified, the taste is slightly spicy and bitter. The white and paeonol are attached to the inner and curved sides, and the stronger the fresh scent, the better the product. A shrub with peonies, planted with flowers or herbs from various places. In the fall, roots are removed, the neck is removed and sunburned. Root bark and cores include the pheonol glycosides phenosides, pheonolides, peonyflorin, benzoic acid, and pheonol. It is used for autonomic nervous system relief as an antipyretic, antipyretic, analgesic, and anti-inflammatory agent. It is also used for menstrual irregularities and back pain. When used together with the skin and peach seeds (doin) increases the anti-inflammatory effect and blood purification. Peony Root bark of Paeonia suffruticosa A. Paeonol and its glycosides, paeonoside, paeonolide, and paeoniflorin. It is contained. This is an essential drug of gynecological drugs, sedative action, fever lowering action, pain relief action, anti-inflammatory action and bloody action and blood pressure lowering action has been reported. Bark skin is known to show anti-inflammatory effect and blood circulation improvement when used in combination with causality. On the other hand, the efficacy of the endothelial skin associated with cosmetics has a boil treatment effect by anti-inflammatory action, tyrosinase activity inhibitory effect, it is known to prevent skin aging by promoting blood circulation and anti-inflammatory action and astringent action.
본 발명에서 사용된 세신(Aiasarum sieboldii Miquel)은 방울풀과(Aristolochiaceae)에 속하는 민족두리풀 및 족두리풀의 뿌리를 말린 것으로 흔히 족두리풀뿌리라고 일컫는다. 고르지 않게 구부러진 노끈모양을 이르고 길이 2~4cm, 지름 2~3mm의 황갈색의 마디가 진 뿌리줄기에 길이 약 15cm, 지름 약 1mm의 뿌리가 많이 달린다. 냄새가 있고 맛은 맵고 혀를 약간 마비시킨다. 그 성분으로는 리그난 화합물인 l-세사민, 1.9∼3.4%의 정유가 들어 있으며, 정유에는 메틸에우게놀, 팔미틴산, 사프롤, 피넨, 치네올, 에우카르본 등이 들어있다. 해열, 진정, 진 통, 항염, 항알레르기 작용, 국소마취작용 및 억균작용이 있다.Seisin (Aiasarum sieboldii Miquel) used in the present invention dried the roots of the Korean cephalopods and the cephalopods belonging to the group Aristolochiaceae and are commonly referred to as the cephalopods. Unevenly bent strings are 2 ~ 4cm long, 2 ~ 3mm in diameter, yellowish brown nodes with roots of about 15cm in length and 1mm in diameter. It smells and tastes spicy and slightly numbs the tongue. Its component contains l-sesamin, a lignan compound, 1.9-3.4% of essential oils, and essential oils include methyleugenol, palmitic acid, saprolol, pinene, cineol and eucarbon. There are antipyretic, soothing, analgesic, anti-inflammatory, anti-allergic, local anesthetic and fungicidal effects.
본 발명에서 사용된 백강잠(Bombyx mori Linn)은 누에나방과(Bombycidae 누에과)의 유충에 백강균(Beauveriabassiana (Bals.) Vuill.)을 접종시킨 유충의 건조충체로서, 이것을 말리거나 석회와 반죽하여 불에 구워 말린 것을 약으로 쓴다. 생약명은 백강잠 또는 강잠(Batyticatus Bombycis, Corpus Bombycis)으로 불려진다. 백강잠은 전통적으로 진경, 진정, 거풍, 소종에 이용되어 왔으며(원색천연물 대사전), 피부염치료제(일본 특개평 5-246874) 등으로 연구되었고, 성분에 대한 연구는 거의 진행되지 않았다.Bombyx mori Linn used in the present invention is a dry worm of the larva inoculated with the larvae of Bombycidae silkworm family (Beauveriabassiana (Bals.) Vuill.), Dried or limed and kneaded Bake and dry it as a medicine. The herbal name is called Batyticatus Bombycis, Corpus Bombycis. Baeksijam has been traditionally used for jinjing, soothing, swelling, and seedling (prime metabolism), and has been studied as a dermatitis treatment (Japanese Patent Application Laid-Open No. 5-246874).
본 발명에서 사용된 지황(Rehmannia glutinosa Libschitz var. purpurea Makino)은 현삼과에 딸린 여러해살이 약용식물로 그 뿌리를 한방에서 약재로 쓰는데, 날 것을 생지황, 말린 것을 건지황이라 하며, 숙지황 중 특히 술에 담갔다가 쪄서 말리기를 9번 되풀이하여 만든 것은 구지황이라 하여 그 약효를 으뜸으로 친다. 허리와 무릎이 시리고 아픈 증상이나 월경이상, 어지럼증 등을 치료하고 머리를 검게 하는 효능이 있다. 또한 피부각화를 예방, 피부를 부드럽게 각질세포를 연화해주며, 혈행 촉진의 특징을 가지고 있다. Rehmannia glutinosa Libschitz var.purpurea Makino used in the present invention is a perennial medicinal plant with a ginseng family, whose roots are used as a medicinal herb in one shot. It is called nine times to make the dried 9 times repeatedly dried, the best effect of the medicine. Lower back and knee pain, painful symptoms, dysmenorrhea, dizziness, etc. to treat the black hair is effective. In addition, it prevents skin keratinization, softens the skin, softens keratinocytes, and promotes blood circulation.
본 발명에서 제공하는 ‘가감천금단’과 ‘가감경옥고’ 와 ‘가감홍옥산' 생약 추출 혼합물 내 각종 생약 성분은 당업계에 공지된 다양한 추출 방법을 이용 하여 수득할 수 있으며, 추출 용매의 종류 및 함량 등도 목적에 따라 임의 선정하여 사용할 수 있다. Various herbal ingredients in the 'Gagamcheon forbidden', 'Gagamgyeongokgo' and 'Gagamhongoksan' herbal extract mixtures provided by the present invention can be obtained by using various extraction methods known in the art, The content and the like can also be arbitrarily selected according to the purpose.
바람직하게는 물, 에탄올, 메탄올, 부탄올, 에틸아세테이트, 부틸렌글리콜 , 함수 프로필렌글리콜, 함수 글리세린, 함수 에탄올, 함수 부틸렌글리콜로 구성된 그룹으로부터 선택된 한 가지 이상의 용매를 사용하여 수득할 수 있다. 또한, 이때 5-20배 부피량의 용매를 가하여 추출하는 것이 바람직하다. Preferably, it can be obtained using one or more solvents selected from the group consisting of water, ethanol, methanol, butanol, ethyl acetate, butylene glycol, hydrous propylene glycol, hydrous glycerin, hydrous ethanol, hydrous butylene glycol. In addition, it is preferable to extract by adding 5-20 times the volume amount of solvent at this time.
한편, 본 발명의 추출물은 상기한 추출 용매 뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 생약 추출물을 수득할 수 있다는 것은 당업자에게 자명한 것이다. On the other hand, it will be apparent to those skilled in the art that the extract of the present invention can obtain a herbal extract having substantially the same effect using not only the aforementioned extraction solvent but also other extraction solvents.
또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물 뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 생약 추출물에 포함되는 것이다.In addition, the extract of the present invention includes not only the extract by the above-mentioned extraction solvent, but also the extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using ultrafiltration membranes having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). The fraction is also included in the herbal extract of the present invention.
본 발명의 생약 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The herbal extract of the present invention may be prepared in powder form by an additional process such as distillation under reduced pressure and freeze drying or spray drying.
생약 혼합 추출물을 통상적인 화장료 조성물에 첨가하여 피부노화방지용 화장료 조성물을 제조할 수 있다. The herbal mixture extract may be added to a conventional cosmetic composition to prepare a cosmetic composition for preventing skin aging.
생약 추출 혼합물의 함량은 각각의 화장료 조성물의 쓰임, 화장료 조성물의 제형 및 피부 상태에 따라서 적절히 선택해야 한다. 생약 추출 혼합물의 함량은 화장료 조성물의 총중량에 대하여 0.001-20 중량%, 바람직하게는 1-10 중량%의 양으로 함유될 수 있다. 상기 혼합물의 함량은 총 중량에 대하여 0.001 중량% 미만일 경우에는 본 발명에서 목적하는 효과를 기대하기가 힘들며, 20 중량% 초과일 경우에는 제형 안정성에 문제가 생길 수 있다.The content of the herbal extract mixture should be appropriately selected according to the use of each cosmetic composition, the formulation of the cosmetic composition and the skin condition. The content of the herbal extract mixture may be contained in an amount of 0.001-20% by weight, preferably 1-10% by weight, based on the total weight of the cosmetic composition. If the content of the mixture is less than 0.001% by weight relative to the total weight, it is difficult to expect the desired effect in the present invention, if it is more than 20% by weight may cause problems in formulation stability.
본 발명에서 제공하는‘가감천금단’과 ‘가감경옥고’ 및 ‘가감홍옥산’은 동시에 적용시 단일 적용시보다 훨씬 우수한 세포증식 및 대사 활성화능을 보이는바, 세 가지 혼합 추출물을 동시에 적용하여 시너지 효과에 의한 피부 세포 활성을 극대화시킬 수 있다. 이 경우‘가감천금단’과 ‘가감경옥고’ 및 ‘가감홍옥산’은 10 : 10: 80 ~ 80:10:10의 중량비로 사용하는 것이 바람직하다. 'Gagamcheon Forbidden' and 'Gagamgyeongokgo' and 'Gagamhongoksan' provided by the present invention show much better cell proliferation and metabolic activation ability than a single application when applied simultaneously, and synergy by applying three mixed extracts simultaneously It is possible to maximize the skin cell activity by the effect. In this case, 'Gagamcheon Geumdan', 'Gagamgyeong Okgo' and 'Gagam Hongoksan' are preferably used in a weight ratio of 10:10:80 to 80:10:10.
본 발명의 화장품 조성물은 유효 성분으로서의 생약 추출물 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료,향료와 같은 통상적인 보조제, 또는 담체를 포함할 수 있다. The cosmetic composition of the present invention may include ingredients conventionally used in cosmetic compositions in addition to the herbal extract as an active ingredient, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments, flavors, or carriers. It may include.
본 발명의 추출물을 유효성분으로 함유하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제하는 것이 바람직하다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제하는 것이 바람직하다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제 등이 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witePSol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Carriers, excipients, and diluents that may be included in the composition containing the extract of the present invention as an active ingredient include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate , Gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is preferable to use diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants that are commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are preferably mixed. In addition to simple excipients, lubricants such as magnesium styrate talc may also be used. Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 조성물은 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 추가로 포함할 수 있다.The composition of the present invention may further comprise a component selected from the group consisting of water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
수용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민 C, 비타민 H 등을 들 수 있으며, 그들의 염 (티아민염산염, 아스코르빈산나트륨염 등)이나 유도체 (아스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 수용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득할 수 있다.The water-soluble vitamins may be any compound that can be incorporated into cosmetics, but preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H, and the like. Their salts (thiamine hydrochloride, sodium ascorbate salt, etc.) and derivatives (ascorbic acid-2-sodium phosphate salt, ascorbic acid-2-magnesium phosphate salt, etc.) may also be used in the water-soluble vitamins that can be used in the present invention. Included. The water-soluble vitamins can be obtained by conventional methods such as microbial transformation, purification from microorganism culture, enzyme or chemical synthesis.
유용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E (d1-알파 토코페롤, d-알파 토코페롤, d-알파 토코페롤) 등을 들 수 있으며, 그들의 유도체 (팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산dl-알파 토코페롤, 니코틴산dl-알파 토코페롤비타민 E, DL-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 유용성 비타민에 포함된다. 유용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소 또는 화학 합성법 등의 통상의 방법에 의해 취득할 수 있다.The oil-soluble vitamin may be any compound that can be incorporated into cosmetics, but preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol), and the like. And derivatives thereof (ascorbic palmitate, ascorbic stearate, ascorbic acid dipalmitate, dl-alpha tocopherol acetate, dl-alpha tocopherolvitamin E, DL-pantothenyl alcohol, D-pantothenyl alcohol, pantothenyl ethyl) Ethers, etc.) are also included in the oil-soluble vitamins used in the present invention. Oil-soluble vitamins can be obtained by conventional methods such as microbial transformation, purification of microorganism culture, enzyme or chemical synthesis.
고분자 펩티드로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 콜라겐, 가수 분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 고분자 펩티드는 미생물의 배양액으로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견섬유 등의 천연물로부터 정제하여 사용할 수 있다.The polymer peptide may be any compound as long as it can be incorporated into cosmetics. Preferably, collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like can be given. Polymeric peptides can be purified and obtained by conventional methods such as purification from microbial cultures, enzymatic methods or chemical synthesis methods, or can be purified and used from natural products such as dermis and pig silk such as pigs and cattle.
고분자 다당으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 히알루론산나트륨, 콘드로이틴 황산 또는 그 염 (나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유동물이나 어류로부터 정제하여 사용할 수 있다.The polymer polysaccharide may be any compound as long as it can be blended into cosmetics. Preferably, hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.) may be mentioned. For example, chondroitin sulfate or its salt, etc. can be normally purified from a mammal or fish.
스핑고 지질로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 세라미드, 피토스핑고신, 스핑고당지질 등을 들 수 있다. 스핑고 지질은 통상 포유류, 어류, 패류, 효모 또는 식물 등으로부터 통상의 방법에 의해 정제하거나 화학 합성법에 의해 취득할 수 있다.The sphingolipid may be any compound as long as it can be blended into cosmetics. Preferably, ceramide, phytosphingosine, sphingosaccharide lipid, etc. may be mentioned. Sphingo lipids can usually be purified from mammals, fish, shellfish, yeasts or plants by conventional methods or obtained by chemical synthesis.
해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 갈조 엑기스, 홍조 엑기스, 녹조 엑기스 등을 들 수 있으며, 또, 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 의해 정제하여 취득할 수 있다.The seaweed extract may be any compound as long as it can be blended into cosmetics. Preferably, the seaweed extract may include brown algae extract, red algae extract, green algae extract, and the like. Also, calginine, arginic acid, sodium arginate, Potassium arginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained by purification from seaweed by conventional methods.
본 발명의 화장료 조성물에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료 조성물에 배합되는 다른 성분을 배합할 수도 있다.In addition to the said essential component, the cosmetic composition of this invention can also mix | blend the other component normally mix | blended with a cosmetic composition as needed.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제 한(制汗)제, 정제수 등을 들 수 있다.Other components that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, Blood circulation accelerators, cold depressants, delimiters, purified water and the like.
유지 성분으로서는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the fat or oil component include ester fats, hydrocarbon fats, silicone fats, fluorine fats, animal fats, and vegetable fats and oils.
에스테르계 유지로서는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디(카프릴,카프린산)프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다.As ester fats and oils, glyceryl tri2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl mystinate, isopropyl palmitate, ethyl stearate, octyl palmitate, isocetyl isostearate, and stearic acid Butyl, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocetyl acid isocetyl, isostyl acid isostearyl, isostaryl palmitate, octylate acid octyldodecyl, isostearic acid isetyl, diethyl sebacate, adipine Acid isopropyl, isoalkyl neopentane, tri (capryl, capric acid) glyceryl, trimethyl ethyl trimethylol propane, triisostearic acid trimethylol propane, tetra 2-ethylhexanoic penta erythritol Cetyl caprylate, lauric acid decyl, hexyl laurate, decyl myristin, myristin acid myristyl, myritic acid cetyl, stearyl stearate, decyl oleate, rininooleic acid , Isostearyl laurate, isotridecyl myristin, isocetyl palmitate, octyl stearate, isocetyl stearate, isodecate oleate, octylate decyl oleate, octyl dodecyl linoleate, isopropyl isopropyl acid, 2 -Cetostearyl ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicapric acid, propylene glycol dicacapate, capric acid Propylene glycol, dicapric acid neopentyl glycol, dioctanoate neopentyl glycol, tricaprylic acid glyceryl, triundecyl glyceryl, triisopalmitinate glyceryl, triisostearate glyceryl, neopentane dodecyl Isostearyl octanoate, octyl isononate, hexyl decyl neodecanoate, octyl dodecyl neodecanoate, isocetyl isostearate, isostearyl isostearate, Sothete octylate, polyglycerol oleate, polyglycerine isostearate, triisocetyl citrate, triisoalkyl citrate, triisoctyl citrate, lauryl lactate, myritic lactate, octyl lactate, octyl lactate, tricitric acid Ethyl, acetyl triethyl citrate, acetyl tributyl citrate, trioctyl citrate, diisostearyl malic acid, 2-ethylhexyl hydroxystearate, di2-ethylhexyl succinate, diisobutyl adipicate, diisopropyl sebacinate, Dioctyl sebacate, cholesteryl stearate, cholesteryl isostearate, cholesteryl hydroxystearate, cholesteryl oleate, dihydrocholesteryl oleate, physteryl isostearate, phytic oleate, 12-Steloylhydroxystearate isocetyl, 12-Steloylhydroxystearate stearyl, 12-steal One hydroxy stearic acid and the like esters such as cetearyl source.
탄화 수소계 유지로서는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로크리스탈린왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다.Hydrocarbon-based fats and oils, such as squalene, a liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, a liquid isoparaffin, polybutene, microcrystal wax, and a vaseline, etc. are mentioned as a hydrocarbon-type fats and oils.
실리콘계 유지로서는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산ㆍ메틸세틸옥시실록산 공중합체, 디메틸실록산ㆍ메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다.Examples of the silicone-based oils and fats include polymethylsilicone, methylphenylsilicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane, methylcetyloxysiloxane copolymer, dimethylsiloxane and methylsteoxysiloxane copolymer, and alkyl. Modified silicone oil, amino modified silicone oil and the like.
불소계 유지로서는 퍼플루오로폴리에테르 등을 들 수 있다.Perfluoro polyether etc. are mentioned as fluorine-based fats and oils.
동물 또는 식물 유지로서는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 새플라워유, 대두유, 옥수수유, 유채유, 행인(杏仁)유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 메도홈유, 난황유, 우지(牛脂), 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀린, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.Animal or vegetable oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, soybean oil, soybean oil, corn oil, rapeseed oil, almond oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil. , Cottonseed oil, Palm oil, Cucumber nut oil, Wheat germ oil, Rice germ oil, Shea butter, Walnut colostrum oil, Marker demia nut oil, Meadow home oil, Egg yolk oil, Uji, Horse oil, Mink oil, Orange rape oil, Jojoba oil And animal or plant fats and oils such as candeler wax, carnava wax, liquid lanolin and hardened castor oil.
보습제로서는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizing agent include a water-soluble low molecular moisturizer, a fat-soluble molecular moisturizer, a water-soluble polymer, and a fat-soluble polymer.
수용성 저분자 보습제로서는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다.Water-soluble low molecular humectants include serine, glutamine, sorbitol, mannitol, pyrrolidone-sodium carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B (polymerization degree n = 2 or more), polypropylene Glycol (polymerization degree n = 2 or more), polyglycerol B (polymerization degree n = 2 or more), lactic acid, lactic acid salt, etc. are mentioned.
지용성 저분자 보습제로서는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다.Examples of the fat-soluble low molecular humectants include cholesterol and cholesterol esters.
수용성 고분자로서는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성 키틴, 키토산, 덱스트린 등을 들 수 있다.Examples of the water-soluble polymer include carboxyvinyl polymer, polyasparaginate, tragacanth, xanthan gum, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, water soluble chitin, chitosan, and dextrin. Can be.
지용성 고분자로서는 폴리비닐피롤리돈ㆍ에이코센 공중합체, 폴리비닐피롤리돈ㆍ헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리 콘 등을 들 수 있다.Examples of the fat-soluble polymers include polyvinylpyrrolidone-eicosene copolymers, polyvinylpyrrolidone-hexadecene copolymers, nitrocellulose, dextrin fatty acid esters, polymer silicones, and the like.
에몰리엔트제로서는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollient include long-chain acyl glutamic acid cholesteryl esters, hydroxy stearic acid cholesterol, 12-hydroxystearic acid, stearic acid, rosin acid, lanolin fatty acid cholesteryl esters, and the like.
계면 활성제로서는 비이온성 계면 활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제 등을 들 수 있다.As surfactant, nonionic surfactant, anionic surfactant, cationic surfactant, amphoteric surfactant, etc. are mentioned.
비이온성 계면 활성제로서는 자기 유화형 모노스테아르산글리세린, 프로필렌글리콜지방산에스테르, 글리세린지방산에스테르, 폴리글리세린지방산에스테르, 솔비탄지방산에스테르, POE (폴리옥시에틸렌)솔비탄지방산에스테르, POE 솔비트지방산에스테르, POE 글리세린지방산에스테르, POE 알킬에테르, POE 지방산에스테르, POE 경화피마자유, POE 피마자유, POEㆍPOP (폴리옥시에틸렌ㆍ폴리옥시프로필렌) 공중합체, POEㆍPOP 알킬에테르, 폴리에테르변성실리콘, 라우린산알카놀아미드, 알킬아민옥시드, 수소첨가대두인지질 등을 들 수 있다.As the nonionic surfactant, self-emulsifying glycerin monostearate, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerol fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbitan fatty acid ester, POE Glycerin fatty acid ester, POE alkyl ether, POE fatty acid ester, POE hardened castor oil, POE castor oil, POE / POP (polyoxyethylene / polyoxypropylene) copolymer, POE / POP alkyl ether, polyether modified silicone, lauric acid Alkanolamide, alkylamine oxide, hydrogenated soybean phospholipid, etc. are mentioned.
음이온성 계면 활성제로서는 지방산비누, 알파-아실술폰산염, 알킬술폰산염, 알킬알릴술폰산염, 알킬나프탈렌술폰산염, 알킬황산염, POE 알킬에테르황산염, 알킬아미드황산염, 알킬인산염, POE 알킬인삼염, 알킬아미드인산염, 알킬로일알킬타우린염, N-아실아미노산염, POE 알킬에테르카르복실산염, 알킬술포숙신산염, 알킬술포아세트산나트륨, 아실화 가수분해 콜라겐펩티드염, 퍼플루오로알킬인산에스테르 등을 들 수 있다.Anionic surfactants include fatty acid soaps, alpha-acyl sulfonates, alkyl sulfonates, alkyl allyl sulfonates, alkyl naphthalene sulfonates, alkyl sulfates, POE alkyl ether sulfates, alkylamide sulfates, alkyl phosphates, POE alkylphosphates, and alkylamides. Phosphates, alkyloylalkyltaurine salts, N-acylamino acid salts, POE alkyl ether carboxylate salts, alkyl sulfosuccinate salts, sodium alkyl sulfo acetates, acylated hydrolyzed collagen peptide salts, perfluoroalkyl phosphate esters, and the like. have.
양이온성 계면 활성제로서는 염화알킬트리메틸암모늄, 염화스테아릴트리메틸 암모늄, 브롬화스테아릴트리메틸암모늄, 염화세토스테아릴트리메틸암모늄, 염화디스테아릴디메틸암모늄, 염화스테아릴디메틸벤질암모늄, 브롬화베헤닐트리메틸암모늄, 염화벤잘코늄, 스테아르산디에틸아미노에틸아미드, 스테아르산디메틸아미노프로필아미드, 라놀린 유도체 제 4급 암모늄염 등을 들 수 있다.As cationic surfactant, alkyltrimethylammonium chloride, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, cetostearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethyl benzyl ammonium bromide, behenyl trimethyl ammonium chloride, chloride Benzalkonium, diethylaminoethyl stearate, dimethylaminopropyl stearate, lanolin derivatives, quaternary ammonium salts, and the like.
양성 계면 활성제로서는 카르복시베타인형, 아미드베타인형, 술포베타인형, 히드록시술포베타인형, 아미드술포베타인형, 포스포베타인형, 아미노카르복실산염형, 이미다졸린 유도체형, 아미드아민형 등의 양성 계면 활성제 등을 들 수 있다.Examples of amphoteric surfactants include the carboxybetaine type, the amide betain type, the sulfobetain type, the hydroxysulfobetain type, the amide sulfobetain type, the phosphobetaine type, the aminocarboxylate type, the imidazoline derivative type, and the amideamine type. An amphoteric surfactant etc. are mentioned.
유기 및 무기 안료로서는 규산, 무수규산, 규산마그네슘, 탤크, 세리사이트, 마이카, 카올린, 벵갈라, 클레이, 벤토나이트, 티탄피막운모, 옥시염화비스무트, 산화지르코늄, 산화마그네슘, 산화아연, 산화티탄, 산화알루미늄, 황산칼슘, 황산바륨, 황산마그네슘, 탄산칼슘, 탄산마그네슘, 산화철, 군청, 산화크롬, 수산화크롬, 칼라민 및 이들의 복합체등의 무기 안료 ; 폴리아미드, 폴리에스테르, 폴리프로필렌, 폴리스티렌, 폴리우레탄, 비닐수지, 요소수지, 페놀수지, 불소수지, 규소수지, 아크릴수지, 멜라민수지, 에폭시수지, 폴리카보네이트수지, 디비닐벤젠ㆍ스티렌 공중합체, 실크파우더, 셀룰로오스, CI 피그먼트옐로우, CI 피그먼트오렌지 등의 유기 안료 및 이들의 무기 안료와 유기 안료의 복합 안료 등을 들 수 있다.Organic and inorganic pigments include silicic acid, silicic anhydride, magnesium silicate, talc, sericite, mica, kaolin, bengala, clay, bentonite, titanium film mica, bismuth oxychloride, zirconium oxide, magnesium oxide, zinc oxide, titanium oxide, aluminum oxide Inorganic pigments such as calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, ultramarine blue, chromium oxide, chromium hydroxide, calamine and composites thereof; Polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluorine resin, silicon resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, divinylbenzene, styrene copolymer, Organic pigments such as silk powder, cellulose, CI pigment yellow, CI pigment orange, and composite pigments of these inorganic pigments and organic pigments;
유기 분체로서는 스테아르산칼슘 등의 금속비누 ; 세틸린산아연나트륨, 라우릴린산아연, 라우릴린산칼슘 등의 알킬인산금속염 ; N-라우로일-베타-알라닌칼슘, N-라우로일-베타-알라닌아연, N-라우로일글리신칼슘 등의 아실아미노산 다가금속염 ; N-라우로일-타우린칼슘, N-팔미토일-타우린칼슘 등의 아미드술폰산 다가금속염 ; N-엡실론-라우로일-L-리진, N-엡실론-팔미토일리진, N-알파-파리토일올니틴, N-알파-라우로일아르기닌, N-알파-경화우지지방산아실아르기닌 등의 N-아실염기성아미노산 ; N-라우로일글리실글리신 등의 N-아실폴리펩티드 ; 알파-아미노카프릴산, 알파-아미노라우린산 등의 알파-아미노지방산 ; 폴리에틸렌, 폴리프로필렌, 나일론, 폴리메틸메타크릴레이트, 폴리스티렌, 디비닐벤젠ㆍ스티렌 공중합체, 사불화에틸렌 등을 들 수 있다.As organic powder, Metal soaps, such as a calcium stearate; Alkyl phosphate metal salts such as sodium cetylinate, zinc lauryl acid and calcium laurate; Acylamino acid polyvalent metal salts such as N-lauroyl-beta-alanine calcium, N-lauroyl-beta-alanine zinc, and N-lauroylglycine calcium; Amide sulfonic acid polyvalent metal salts, such as N-lauroyl-taurine calcium and N-palmitoyl-taurine calcium; N-epsilon-lauroyl-L-lysine, N-epsilon-palmitolyzine, N-alpha-paratoylol nitin, N-alpha-lauroyl arginine, N-alpha-cured fatty acid acyl arginine -Acyl basic amino acid; N-acyl polypeptides, such as N-lauroyl glycyl glycine; Alpha-amino fatty acids such as alpha-aminocaprylic acid and alpha-aminolauric acid; Polyethylene, polypropylene, nylon, polymethyl methacrylate, polystyrene, divinylbenzene-styrene copolymer, ethylene tetrafluoride and the like.
자외선 흡수제로서는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of the ultraviolet absorber include paraaminobenzoic acid, ethyl paraaminobenzoate, amyl paraaminobenzoic acid, octyl paraaminobenzoate, ethylene glycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylic acid and benzyl cinnamic acid. , Paramethoxy cinnamic acid-2-ethoxyethyl, paramethoxy cinnamic acid octyl, diparamethoxy cinnamic acid mono-2-ethylhexaneglyceryl, paramethoxy cinnamic acid isopropyl, diisopropyl diisopropyl cinnamic acid ester mixture, wuro Canonic acid, ethyl urokanoate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenonesulfonic acid and salts thereof, dihydroxymethoxybenzophenone, dihydroxymethoxybenzophenone sodium sulfonate, dihydroxybenzophenone , Tetrahydroxybenzophenone, 4- tert -butyl-4'-methoxydibenzoylmethane, 2,4,6-trianilino- p- (carbo-2'-ethylhexyl-1'-oxy) -1 , 3,5-triazine, 2- (2-hi And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.
살균제로서는 히노키티올, 트리클로산, 트리클로로히드록시디페닐에테르, 크로르헥시딘글루콘산염, 페녹시에탄올, 레조르신, 이소프로필메틸페놀, 아줄렌, 살리칠산, 진크필리티온, 염화벤잘코늄, 감광소 301 호, 모노니트로과이어콜나트륨, 운데시렌산 등을 들 수 있다.As fungicides, hinokithiol, trichloric acid, trichlorohydroxydiphenyl ether, chlorhexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, ginxitlionone, benzalkonium chloride, photosensitive Sodium No. 301, sodium mononitroguicol, undecylenic acid, and the like.
산화 방지제로서는 부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산 등을 들 수 있다.Examples of the antioxidant include butylhydroxyanisole, propyl gallic acid, and erythorbic acid.
pH 조정제로서는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjuster include citric acid, sodium citrate, malic acid, sodium malate, fmaric acid, sodium pmarate, succinic acid, sodium succinate, sodium hydroxide, sodium dihydrogen phosphate, and the like.
알코올로서는 세틸알코올 등의 고급 알코올을 들 수 있다.Examples of the alcohol include higher alcohols such as cetyl alcohol.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또한, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하다. In addition, the compounding component which may be added other than this is not limited to this, In addition, any of the above components can be mix | blended within the range which does not impair the objective and effect of this invention.
본 발명에 따른 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 팩 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 바람직하게는 화장수, 영양로션, 영양크림, 마사지 크림, 에센스, 팩 등의 제형으로 제조될 수 있다. Cosmetic compositions according to the invention can be prepared in any formulations conventionally prepared in the art, for example solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing It may be formulated as a cleansing, oil, powder foundation, emulsion foundation, wax foundation, pack, spray, and the like, but is not limited thereto. More preferably, it may be prepared in a formulation such as lotion, nutrition lotion, nutrition cream, massage cream, essence, pack, and the like.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해 화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다. When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic esters, polyethylene glycols or sorbitan may be used.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명에 따른 피부 노화 방지용 화장료 조성물은 세포증식 및 대사 활성 효과를 가짐을 특징으로 한다. 본 발명은 상기 특징으로부터 세포의 turn-over가 증가되어 노화된 피부 세포가 재생되고, 세포에서 생성되는 세포외 간질의 합성을 증가시키는바 피부의 탄력성, 신진대사, 생기 등에 직접 관여하는 세포외 간질의 합성량 증가에 의해 피부 탄력 증가, 피부 신진 대사 촉진 및 피부 생기 증강을 통하여 피부 노화를 방지하는 효과를 가진다. Skin anti-aging cosmetic composition according to the present invention is characterized by having a cell proliferation and metabolic activity effect. The present invention is to increase the turn-over of the cell from the above characteristics to regenerate aging skin cells, increase the synthesis of extracellular epilepsy produced in the cell extracellular epilepsy directly involved in skin elasticity, metabolism, vitality, etc. The increase in the amount of the compound has the effect of preventing skin aging through increased skin elasticity, promote skin metabolism and enhance skin vitality.
본 발명에 따른 피부 노화 방지용 화장료 조성물은 프리 라디칼 소거효과를 가짐을 특징으로 한다. 본 발명은 상기 특징으로부터 피부 주름 생성 억제 및 개선, 피부 탄력 증가를 통하여 피부 노화를 방지하는 효과를 가진다. The cosmetic composition for preventing skin aging according to the present invention is characterized by having a free radical scavenging effect. The present invention has the effect of preventing the skin aging through the skin wrinkle suppression and improvement, skin elasticity increase from the above characteristics.
본 발명에 따른 피부 노화 방지용 화장료 조성물은 콜라겐 생산촉진 효과를 가짐을 특징으로 한다. 본 발명은 상기 특징으로부터 피부 주름 생성 억제 및 개선, 피부 탄력 증가를 통하여 피부 노화를 방지하는 효과를 가진다. Skin anti-aging cosmetic composition according to the invention is characterized in that it has a collagen production promoting effect. The present invention has the effect of preventing the skin aging through the skin wrinkle suppression and improvement, skin elasticity increase from the above characteristics.
본 발명은 상기 특징들으로부터 피부 주름 생성 억제 및 개선, 피부 탄력 증가, 피부 신진 대사 촉진 및 피부 생기 증강을 통하여 피부 노화를 방지하는 효과를 가지는 바 본 발명에서의 용어 "피부 노화 방지"는 주름 개선, 피부 탄력 개선, 피부 신진 대사 촉진 및 피부 생기 증강을 포함하는 의미로 해석된다. 또한, 상기 용어 "피부 노화 방지"는 피부 노화 예방, 개선 및 치료를 포함하는 의미를 갖는다. The present invention has the effect of preventing skin aging through the inhibition and improvement of skin wrinkle generation, increase skin elasticity, promote skin metabolism and enhance skin vitality from the above characteristics bar term "anti-aging skin" in the present invention is wrinkle improvement It is interpreted as meaning including improving skin elasticity, promoting skin metabolism and enhancing skin vitality. The term "anti-aging of skin" also has the meaning of preventing, improving and treating skin aging.
본 발명의 다른 양태에 따르면, 건조된 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠을 용매에 넣고 60~80℃에서 2~5시간 가온하여 추출한 후 여과하고 냉각한 후 5-15℃에서 4~14일간 숙성시킨 후 여과하여 생약 추출 혼합물 A을 제조하고, 건조된 인삼, 지황 및 꿀을 용매에 넣고 60~80℃에서 2~5시간 가온하여 추출한 후 여과하고 냉각한 후 5-15℃에서 4~14일간 숙성시킨 후 여과하여 생약 추출 혼합물 B를 제조하고, 건조된 행인, 과루근 및 백봉령을 용매에 넣고 60~80℃에서 2~5시간 가온하여 추출한 후 여과하고 냉각한 후 5-15℃에서 4~14일간 숙성시킨 후 여과하여 생약 추출 혼합물 C를 제조하여, 생약 추출 혼합물 A, B, C를 혼합하는 피부 노화 방지용 화장료 조성물 제조방법을 제공한다. According to another embodiment of the present invention, dried dried white paper, ginkoin, cheongung, dongle, sessin, earthen root, doin, neck skin, shinyi, saengsonghyang and Baekjap in a solvent and warmed at 60 ~ 80 ℃ for 2 to 5 hours After extraction, the mixture was filtered, cooled, and aged for 4 to 14 days at 5-15 ° C., followed by filtration to prepare a herbal extract mixture A. The dried ginseng, turmeric and honey were put in a solvent and warmed at 60 to 80 ° C. for 2 to 5 hours. After extraction, the resultant was filtered, cooled and aged for 4-14 days at 5-15 ° C., followed by filtration to prepare a herbal extract mixture B, and dried dried almonds, fruit roots and Baekbongryeong in a solvent at 2˜5 ° C. at 60 ° C. to 80 ° C. After extracting by heating for a period of time, filtered, cooled and aged for 4-14 days at 5-15 ℃ and then filtered to prepare a crude drug extract mixture C, a method for producing a skin anti-aging cosmetic composition for mixing the herbal extract mixture A, B, C To provide.
상기 건조된 생약 성분들을 용매에 넣고 추출한 후 냉각은 상온에서 하는 것 이 바람직하나 이에 제한되지 않는다. Cooling is preferably performed at room temperature after extraction of the dried herbal ingredients into a solvent, but is not limited thereto.
상기 생약 추출 혼합물 A,B,C를 제조하는 순서에는 제한이 없다. The order of preparing the herbal extract mixtures A, B and C is not limited.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시 예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it is to those skilled in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. Will be self-evident.
상기와 같이 본 발명에 따른 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 혼합 추출물('가감천금단')과 인삼, 지황 및 꿀로 이루어진 혼합추출물('가감경옥고'), 행인, 과루근 및 백봉령으로 이루어진 혼합 추출물('가감홍옥산')을 유효성분으로 함유하는 피부 노화 방지용 화장료 조성물은 피부에 대한 부작용 없이 안전하게 사용할 수 있다. 뿐만 아니라 세포증식 및 대사 활성 증진, 프리 라디칼 소거, 콜라겐 생산촉진에 의한 피부 주름 개선과 피부 탄력 개선을 통하여 피부 노화를 방지 및 개선한다. White ginseng, Dongguin, Cheongung, Dongle, Seshin, Earthen root, Doin, Peelwood, Sinyi, Gamsonghyang and Baekjajam according to the present invention as described above ('Gagamcheoncheondan') and made of ginseng, jihwang and honey Skin anti-aging cosmetic composition containing a mixed extract ('gagamyeongokgo'), almonds, fruit roots and baekbongyeong ('gagamhongoksan') as an active ingredient can be used safely without side effects on the skin. In addition, it prevents and improves skin aging by improving cell proliferation and metabolic activity, free radical scavenging, and improving skin wrinkles and skin elasticity by promoting collagen production.
제조 실시예 1~10 : 가감천금단 혼합 추출물의 제조 Preparation Examples 1-10: Preparation of Gagamcheon Forbidden Mixture Extract
건조된 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송 향, 백강잠을 증류수 5kg에 넣고 냉각 콘덴서가 달린 추출기를 사용하여 70℃에서 3시간 가온하여 추출한 후 400 메쉬 여과포(whatman)로 여과하고 상온으로 냉각한 후 5-15℃에서 7일간 방치하여 숙성시킨 후 0.45 μm필터로 여과하여 4.3kg 의 추출물을 얻었다. Dried white paper, Dongguin, Cheongung, Dongle, Sessin, Earthen root, Doin, Bark skin, Sinyi, Gamyang incense, Baeksijam in distilled water 5kg and extracted by heating at 70 ℃ for 3 hours using an extractor equipped with cooling condenser After filtering with a mesh filter cloth (whatman), cooled to room temperature and left to mature for 7 days at 5-15 ℃, and filtered with a 0.45 μm filter to obtain 4.3 kg of extract.
제조실시예 11~20 : 가감경옥고 혼합 추출물의 제조 Preparation Examples 11-20 : Preparation of Gagamgogo Mixed Extract
건조된 인삼, 지황, 꿀을 증류수 2kg에 넣고 냉각 콘덴서가 달린 추출기를 사용하여 70℃에서 3시간 가온하여 추출한 후 400 메쉬 여과포(whatman)로 여과하고 상온으로 냉각한 후 5-15℃에서 7일간 방치하여 숙성시킨 후 0.45μm필터로 여과하여 1.6kg 의 추출물을 얻었다. Dry ginseng, turmeric and honey in 2kg of distilled water and extracted by heating at 70 ℃ for 3 hours using an extractor equipped with cooling condenser, filtered with 400 mesh filter cloth (whatman) and cooled to room temperature for 7 days at 5-15 ℃. After standing to age, it was filtered through a 0.45μm filter to obtain 1.6kg of extract.
제조실시예 21~30 : 가감홍옥산 혼합 추출물의 제조 Preparation Examples 21-30: Preparation of gagamhongoksan mixed extract
건조된 행인, 과루근, 백봉령을 증류수 2kg에 넣고 냉각 콘덴서가 달린 추출기를 사용하여 70℃에서 3시간 가온하여 추출한 후 400 메쉬 여과포(whatman)로 여과하고 상온으로 냉각한 후 5-15℃에서 7일간 방치하여 숙성시킨 후 0.45μm필터로 여과하여 1.4kg 의 추출물을 얻었다. Dry dried almonds, fruit roots and Baekbongryeong in 2kg of distilled water and extracted by heating at 70 ° C for 3 hours using an extractor equipped with a cooling condenser. After standing for one day and aged, the resultant was filtered with a 0.45 μm filter to obtain 1.4 kg of extract.
실험예Experimental Example 1~7 1-7
하기 실험예 1~7은 상기 제조실시예의 제조방법에 따라 에탄올 30%의 용매로 추출된 생약 혼합 추출물을 evaporator를 사용하여 감압, 농축하여 파우더로 제조하여 실험한 것이다. Experimental Examples 1 to 7 below were prepared by experimenting the crude drug mixture extract extracted with a solvent of 30% ethanol under reduced pressure and concentration using an evaporator to prepare a powder.
실험예Experimental Example 1. 세포독성 1. Cytotoxicity
혼합 추출물에 대하여 단층 세포 배양에서의 세포독성을 측정하였다.Cytotoxicity in monolayer cell cultures was measured for the mixed extracts.
실험 방법Experiment method
MTT assay [참고문헌: Mossman T. (1983) Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55~63]는 살아있는 세포의 수를 측정함으로서 세포 증식이나 독성에 많이 사용되는 실험법으로 표준 비색분석법(standard colorimetric assay)이라고 할 수 있다. 살아있는 세포의 미토콘드리아 내에서 노란색의 수용성 기질인 MTT(3-[4,5- dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide,Thiazolyl Blue Tetrazolium Bromide)가 탈수소 효소작용(succinate dehydrogenase 또는 mitochondrial dehydrogenase라고도 불림)에 의해 비수용성인 파란색의 포르마잔(formazan) 유도체로 환원되는 원리를 이용하는 것이다. 생성된 포르마잔 유도체는 용해제(보통 DMSO(dimethylsulfoxide) 사용)를 넣고 용해시킨 후 흡광도를 측정한다. 생성된 포르마잔 유도체는 DMSO에 용해되고 흡광도 (Optical Density)를 측정한다. 측정된 흡광도는 살아있는 세포의 수와 직선적인 상관관계를 나타내게 된다.MTT assay [Reference: Mossman T. (1983) Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55 ~ 63] is a standard colorimetric assay that is widely used for cell proliferation and toxicity by measuring the number of living cells. MTT (3- [4,5-dimethylthiazole-2-yl] -2,5-diphenyltetrazolium bromide, Thiazolyl Blue Tetrazolium Bromide), a yellow water-soluble substrate in mitochondria of living cells, is also known as dehydrogenase (succinate dehydrogenase or mitochondrial dehydrogenase). Is reduced to a water-insoluble blue formazan derivative. The resulting formazan derivative is dissolved by adding a dissolving agent (usually using DMSO (dimethylsulfoxide)) and measuring the absorbance. The resulting formazan derivative is dissolved in DMSO and the optical density is measured. The absorbance measured is linearly correlated with the number of living cells.
보다 구체적으로 설명하면, human fibroblasts cell line (ATCC, CRL-2310)을 1x104cells/ml의 농도로 하여 24well plate에 접종하였다. 배지는 소혈청 10%를 함유한 DMEM (Dubelcco'S Modified Eagle Medium, BRL, USA)를 사용하였다. 접종 후 24시간 후 소혈청 2%를 함유한 DMEM (Dubelcco'S Modified Eagle Medium, BRL, USA)으로 교체하고, 시험 시료를 50㎍/㎖의 농도로 10㎕ 첨가한 후 3일 동안 37℃, 5% CO2 인큐베이터에서 배양하였다. 배양이 끝난 후 상등액을 제거하고 다시 PBS(phosphate buffered saline) 200ul씩을 가하여 세척하고 MTT 용액을 well당 1.0㎖씩 가한 후 4시간 후에 MTT를 제거하고 DMSO(Dimethy 1 Sulfoxide)를 well당 1.0㎖씩 가한 후 하룻밤 37℃에서 인큐베이션 후 ELISA reader(sunrise, Austria)를 사용하여 wave length 570nm에서 흡광도를 측정하였다. 그 결과를 표1에 나타내었다. More specifically, human fibroblasts cell line (ATCC, CRL-2310) was inoculated in a 24well plate at a concentration of 1x10 4 cells / ml. Medium was used DMEM (Dubelcco'S Modified Eagle Medium, BRL, USA) containing 10% bovine serum. 24 hours after inoculation, it was replaced with DMEM (Dubelcco'S Modified Eagle Medium, BRL, USA) containing 2% of bovine serum, and 10 μl of test sample was added at a concentration of 50 μg / ml. Incubated in a CO 2 incubator. After the incubation, the supernatant was removed and washed again by adding 200ul of PBS (phosphate buffered saline), 1.0ml of MTT solution was added per well, MTT was removed after 4 hours, and DMSO (Dimethy 1 Sulfoxide) was added 1.0ml per well. After incubation at 37 ℃ overnight, the absorbance was measured at a wave length of 570nm using an ELISA reader (sunrise, Austria). The results are shown in Table 1.
표 1. 혼합 추출물의 단층 세포배양에서의 세포독성Table 1. Cytotoxicity in Monolayer Cell Culture of Mixed Extracts
표 1의 결과에서 보듯이 가감천금단, 가감경옥고, 가감홍옥산은 모두 세포생존율이 100%이상인바, 안전성이 매우 우수함을 알 수 있다. As shown in the results of Table 1, the Gagamcheon forbidden, Gagam Gyeongokgo, Gagam Hongoksan all have a cell survival rate of 100% or more, it can be seen that the safety is very excellent.
실험예Experimental Example 2. 2. 프리라디칼Free radical 소거 실험 (1) Elimination Experiment (1)
상기 혼합 추출물에 대하여 히드록실 라디칼소거 효과를 측정하였다.The hydroxyl radical scavenging effect of the mixed extract was measured.
실험 방법Experiment method
사람 섬유아세포를 2×105세포/웰로 웰 플래이트에 놓고 10 % FBS함유하는 EMEM 배지(Eagle's minimum essential medium, BRL , USA)를 0.2㎖을 깐 다음 24시간 동안 CO2 배양기에서 배양한다. 여기에 DMSO에 녹인 혼합 추출액을 처리하고, 히드록실 라디칼을 발생시키기 위하여 30mM H2O2를 가한 후 24시간 동안 배양한다. 그 다음 배양한 세포의 증식율을 알아보기 위하여 MTT assay를 수행한다. MTT assay는 배양한 세포에 MTT 용액 0.1㎖을 가한 후 4시간 동안 배양한 다음 배지는 제거하고 DMSO 0.5㎖를 넣어 형성된 포르마잔을 ELISA reader(sunrise, Austria)를 사용해 570㎚에서 흡광도를 측정하는 방식으로 수행하였다. 양성 대조군은 라디칼 소거 능이 뛰어난 EGCG(epigallocatechin gallate)를 사용하였다. 상기 실험군과 대조군에 대한 흡광도 측정후, 하기 수학식 1를 이용하여 자유라디칼 소거활성 효과를 구하여 그 결과를 하기 표 2에 나타내었다. Human fibroblasts are placed on the well plate at 2 × 10 5 cells / well and 0.2 ml of EMEM medium (Eagle's minimum essential medium, BRL , USA ) containing 10% FBS is incubated in a CO 2 incubator for 24 hours. The mixed extract dissolved in DMSO is treated and 30mM H 2 O 2 is added to induce hydroxyl radicals, followed by incubation for 24 hours. Then, MTT assay is performed to determine the growth rate of the cultured cells. In MTT assay, 0.1 ml of MTT solution was added to the cultured cells, followed by incubation for 4 hours. The medium was removed, and 0.5 ml of DMSO was added. Formazan was measured using an ELISA reader (sunrise, Austria) to measure absorbance at 570 nm. Was performed. As a positive control, EGCG (epigallocatechin gallate) with excellent radical scavenging ability was used. After absorbance measurement for the experimental group and the control group, the free radical scavenging activity was obtained using Equation 1 below and the results are shown in Table 2 below.
수학식 1Equation 1
히드록실라디칼저해효과(%)=((실험군의 흡광도)/(대조군의 흡광도))x100Hydroxyl radical inhibition effect (%) = ((absorbance of experimental group) / (absorbance of control group)) x100
실험군 : 시료 처리군Experimental group: sample treatment group
대조군 : 시료 무처리군(다른 실험 조건은 모두 동일)Control group: sample untreated group (all other experimental conditions are the same)
표 2. 혼합 추출물에 대한 히드록실 라디칼 소거 효과 Table 2. Hydroxyl Radical Scavenging Effects on Mixed Extracts
상기 표 2에 나타낸 결과를 통해 확인할 수 있는 바와 같이, 본 발명의 생약추출 혼합물은 히드록실 라디칼 소거능력이 매우 탁월하고, 농도가 증가할수록 라디칼 소거능력이 더 증가 된다는 것을 확인할 수 있었다.As can be seen from the results shown in Table 2, the herbal extract mixture of the present invention was confirmed that the hydroxyl radical scavenging ability is very excellent, and as the concentration increases, the radical scavenging ability is further increased.
실험예Experimental Example 3. 3. 프리라디칼Free radical 소거 효과 실험 (2) Elimination effect experiment (2)
상기의 혼합 추출물에 대하여 과산화물 라디칼소거 효과(항산화 효과)를 측정하였다.The peroxide radical scavenging effect (antioxidant effect) was measured for the mixed extract.
실험 방법Experiment method
사람 섬유아 세포를 2×105세포/웰로 웰 플래이트에 놓고 10 % FBS함유하는 EMEM 배지 0.2㎖를 깐 다음, 24시간 동안 CO2 배양기에서 배양한다. 여기에 DMSO에 녹인 혼합 추출액을 처리하고 30분 동안 배양한다. 이 배양된 세포에 1.5mM 크산틴 10㎕ 과 0.25U 크산틴 산화효소 10㎕를 가하여 과산화물 라디칼을 발생시킨 후 24시간 동안 CO2 배양기에서 배양하였다. 배양한 세포의 증식율을 알아보기 위하여 MTT assay를 수행한다. MTT assay는 배양한 세포에 MTT 용액 0.1㎖을 가한 후 4시간동안 배양한 다음 배지는 제거하고 DMSO 0.5㎖를 넣어 형성된 포르마잔을 ELISA reader(sunrise, Austria)를 사용해 570㎚에서 흡광도를 측정함으로써 수행하였다. 양성 대조군은 라디칼 소거 능이 뛰어난 EGCG(epigallocatechin gallate)를 사용하였다. 상기 실험군과 대조군에 대한 흡광도 측정후, 하기 수학식 2를 이용하여 자유라디칼 소거활성 효과를 구하여 그 결과를 하기 표 3에 나타내었다. Human fibroblasts are placed on the well plate at 2 × 10 5 cells / well, covered with 0.2 ml of EMEM medium containing 10% FBS, and incubated in a CO 2 incubator for 24 hours. This is treated with a mixed extract dissolved in DMSO and incubated for 30 minutes. 10 µl of 1.5 mM xanthine and 10 µl of 0.25 U xanthine oxidase were added to the cultured cells to generate peroxide radicals, and then cultured in a CO 2 incubator for 24 hours. MTT assay is performed to determine the growth rate of the cultured cells. MTT assay was performed by adding 0.1 ml of MTT solution to the cultured cells, incubating for 4 hours, removing the medium and adding 0.5 ml of DMSO, and measuring the absorbance at 570 nm using ELISA reader (sunrise, Austria). It was. As a positive control, EGCG (epigallocatechin gallate) with excellent radical scavenging ability was used. After measuring the absorbance for the experimental group and the control group, the free radical scavenging activity was obtained using Equation 2 below and the results are shown in Table 3 below.
수학식 2Equation 2
과산화물 라디칼저해효과(%)=((실험군의 흡광도)/(대조군의 흡광도))x100Peroxide radical inhibition effect (%) = ((absorbance of experimental group) / (absorbance of control group)) x100
실험군 : 시료 처리군Experimental group: sample treatment group
대조군 : 시료 무처리군(다른 실험 조건은 모두 동일)Control group: sample untreated group (all other experimental conditions are the same)
표 3. 혼합 추출물에 대한 과산화물 라디칼 소거 효과 Table 3. Peroxide Radical Scavenging Effects on Mixed Extracts
상기 표 3에 나타난 결과를 통해 확인할 수 있는 바와 같이, 본 발명의 생약추출 혼합물은 과산화물 라디칼 소거능력이 매우 탁월하며, 농도가 증가할수록 라디칼 소거능력이 더 증가 됨을 확인할 수 있었다.As can be seen through the results shown in Table 3, the herbal extract mixture of the present invention was very excellent peroxide radical scavenging ability, it was confirmed that the radical scavenging ability is increased as the concentration increases.
실험예Experimental Example 4. 세포 대사활성 촉진 및 시너지 효과 실험 4. Promotion of cell metabolism activity and synergy effect experiment
상기 혼합 추출물에 대하여 세포대사 활성 및 시너지 효과를 측정하였다.The metabolic activity and synergistic effect of the mixed extract was measured.
실험 방법Experiment method
이 실험은 세포가 성장하는데 필요한 영양분과 각종 호르몬을 가지고 있는 FBS(fetal bovine serum)을 가한 것과 가하지 않고 대신 혼합 추출물을 넣은 것의 세포 증식능을 비교하는 실험으로 이로써 혼합 추출물의 대사 활성 촉진에 의한 세 포 증식에 미치는 효과를 알 수 있다. This experiment is to compare the cell proliferation ability of FBS (fetal bovine serum) containing nutrients and various hormones needed for cell growth with added mixed extract instead. The effect on proliferation can be seen.
신생아의 포피(foreskin)조직에서 얻은 섬유아 세포를 24웰 플래이트에 웰당 2x103cell수가 되도록 넣어준 후 24시간 배양하였다. 여기에 한쪽에는 DMEM배지에 혼합 추출물을 넣고 대조군에는 DMEM배지에 10% FBS(fetal bovine serum)을 가한다. 4일 동안 배양시킨 후, 세포의 증식율을 알아보기 위하여 MTT assay를 수행한다. MTT assay는 배양한 세포에 MTT 용액 0.1㎖을 가한 후 4시간 동안 배양한 다음 배지는 제거하고 DMSO 0.5㎖를 넣어 형성된 포르마잔을 ELISA reader(sunrise, Austria)를 사용해 570㎚에서 흡광도를 측정하였다. 상기 실험군과 대조군에 대한 흡광도 측정 후, 하기 수학식 3를 이용하여 세포대사활성효과를 구하여 그 결과를 하기 표 4에 나타내었다. Fibroblasts from neonatal foreskin tissue were placed in a 24-well plate at 2 × 10 3 cells per well and incubated for 24 hours. One side of the mixed extract in DMEM medium and 10% FBS (fetal bovine serum) in DMEM medium is added to the control. After incubation for 4 days, MTT assay is performed to determine the proliferation rate of the cells. In the MTT assay, 0.1 ml of MTT solution was added to the cultured cells, followed by incubation for 4 hours. The medium was removed, and 0.5 ml of DMSO was added thereto. After measuring the absorbance for the experimental group and the control group, the cell metabolic activity was obtained using Equation 3 below and the results are shown in Table 4 below.
수학식 3Equation 3
실험군의 세포 대사활성 촉진효과(%)Cell metabolic activity promoting effect of the experimental group (%)
=((실험군의 흡광도)/(음성대조군의 흡광도))x100= ((Absorbance of experimental group) / (absorbance of negative control group)) x100
대조군의 세포 대사활성 촉진효과(%)Cell metabolic activity promoting effect of the control group (%)
=((대조군의 흡광도)/(음성대조군의 흡광도))x100= ((Absorbance of control) / (negative control)) x100
실험군 : FBS 0% + 시료 처리군Experimental group: FBS 0% + sample treatment group
대조군 : FBS 10% + 시료 무처리군(다른 실험 조건은 모두 동일)Control group: FBS 10% + sample untreated group (all other experimental conditions are the same)
음성대조군: FBS 0% Negative Control: FBS 0%
표 4. 혼합 추출물에 대한 세포대사 활성 촉진 효과 Table 4. Effect of promoting cell metabolism activity on mixed extract
상기 표 4에 나타낸 결과를 통해 확인할 수 있는 바와 같이, 본 발명의 생약추출 혼합물을 첨가한 경우 FBS를 첨가했을 때에 못지않은 세포대사 활성 촉진 효과를 나타내었으며, 농도가 증가할수록 세포 대사 활성 촉진 효과는 더욱 증가하는 결과를 보였다. 또한, 가감천금단, 가감경옥고, 가감홍옥산을 함께 첨가한 경우 각각 첨가한 경우에 비해 보다 향상된 세포 대사 활성 촉진 효과를 나타내었다. As can be seen from the results shown in Table 4, the addition of the herbal extract mixture of the present invention showed the same effect as promoting the cell metabolism activity when FBS was added, and as the concentration increases the effect of promoting cell metabolism activity The results were further increased. In addition, the addition of the Gagamcheon forbidden, Gagam Gyeongok, and Gagamhongoksan showed a more enhanced effect of promoting cell metabolism than when added respectively.
실험예Experimental Example 5. 세포 증식 효과 및 시너지 효과 실험 5. Cell proliferation effect and synergy effect experiment
상기 혼합 추출물에 대하여 세포증식 및 시너지 효과를 측정하였다.Cell growth and synergy were measured for the mixed extract.
실험 방법Experiment method
96 마이크로웰 플래이트(96 well plate, Corning사)에 5% 어린 송아지 혈 청(FBS) 용액을 100ul씩 넣은 다음, 2% FBS 가 함유된 DMEM 배지에 일정농도 분산시켜 묽힌 시료를 100ul씩 다시 첨가하고 MTT assay를 수행하여 세포 증식 정도를 평가하였다. 신생아의 포피(foreskin)조직에서 얻은 섬유아세포를 웰당 4000개씩 100ul의 DMEM 배지에 분산시켜 가한 후 7일간 배양하였다. 배양이 끝난 후 상등액을 제거하고 다시 5%PBS(phosphate buffered saline) 200ul씩을 가하여 세척하고 DMSO를 well당 150ul씩 가한 후 10분간 흔들어 녹인 후 570nm에서 ELISA reader(sunrise, Austria)로 흡광도를 측정하였다. 이때 혼합 추출물을 첨가하지 않고 같은 방법으로 실험을 진행한 것을 대조군으로 하여 상대적인 흡광도의 차이로부터 세포증식 효과를 비교하였다. 상기 실험군과 대조군에 대한 흡광도 측정 후, 하기 수학식 4를 이용하여 세포증식효과를 구하여 그 결과를 하기 표 5에 나타내었다. 100 μl of 5% young calf serum (FBS) solution was added to 96 microwell plate (96 Corning), and then dispersed in DMEM medium containing 2% FBS. MTT assay was performed to evaluate the degree of cell proliferation. Fibroblasts from neonatal foreskin tissues were dispersed in 100 ul DMEM medium per well and cultured for 7 days. After the incubation, the supernatant was removed and washed again by adding 200ul of 5% PBS (phosphate buffered saline), and 150ul of DMSO was added per well, and then shaken for 10 minutes. At this time, the experiment was performed in the same manner without adding the mixed extract as a control group and the cell proliferation effect was compared from the difference in relative absorbance. After measuring the absorbance for the experimental group and the control group, using the following equation 4 to obtain the cell proliferation effect is shown in Table 5 below.
수학식 4Equation 4
세포증식효과(%)=((실험군의 흡광도)/(대조군의 흡광도))x100Cell proliferation effect (%) = ((absorbance of experimental group) / (absorbance of control group)) x100
실험군 : 시료 처리군Experimental group: sample treatment group
대조군 : 시료 무처리군(다른 실험 조건은 모두 동일)Control group: sample untreated group (all other experimental conditions are the same)
표 5. 혼합 추출물에 대한 세포증식 및 시너지 효과 Table 5. Cell Proliferation and Synergy Effects on Mixed Extracts
대조군(2% FBS 배지):100%Control (2% FBS Medium): 100%
상기 표 5에 나타난 결과에서 알 수 있듯이, 생약추출 혼합물을 처리하지 않은 대조군과 비교하여, 생약추출 혼합물이 처리된 실험군의 경우 매우 높은 섬유아세포 증식 효과를 나타낸다. 또한, 가감천금단과 가감경옥고 가감혹옥산을 각각 처리한 실험군에 비하여 세가지 생약추출 혼합물을 함께 처리한 실험군이 보다 월등한 세포 증식 효과를 나타낸다. As can be seen from the results shown in Table 5, the experimental group treated with the herbal extract mixture shows a very high fibroblast proliferation effect compared to the control group without the herbal extract mixture. In addition, the experimental group treated with three herbal extract mixtures showed a superior cell proliferation effect, compared to the experimental group treated with Gagamcheon forbidden and Gagamgyeongokgo gagamgamoxane, respectively.
실험예Experimental Example 6. 6. typetype Ⅰ 콜라겐 Ⅰ Collagen 생합성량Biosynthesis
혼합 추출물에 대하여 type Ⅰ 콜라겐 생합성량을 측정하였다. (Kanayama. N., and Terao, T.1992, Gynecol. Obstet. Invest. 34, 24-26)The type I collagen biosynthesis was measured for the mixed extract. (Kanayama. N., and Terao, T. 1992, Gynecol. Obstet. Invest. 34, 24-26)
실험 방법Experiment method
섬유아세포에서 배지로 배출되는 콜라겐 합성 양을 측정하기 위하여 procollagen type I C-peptide ELA kit(TaKaRa사, cat.# MK101)을 사용하였다. KIT을 사용하기 전 human fibroblasts cell line (ATCC, CRL-2310)을 1x104 cells/ml의 농도로 하여 24well plate(24 well plate, Corning사)에 접종하였다. 배지는 FBS(소혈청) 10%를 함유한 DMEM (Dubelcco'S Modified Eagle Medium, BRL, USA)를 사용하였다. 접종 후 24시간 후 시험 시료를 50㎍/㎖의 농도가 되도록 10㎕ 첨가하고 24시간 동안 37℃, 5% CO2 인큐베이터에서 배양하였다. 배양한 배지를 E-tube로 옮기고 15,000rpm에서 30초 동안 원심분리 하였다. 각 웰의 상층액을 모아 프로콜라겐(procollagen) 타입 I C-펩타이드 (PIP) 양을 키트 (Takara, 일본국)를 이용하여 측정함으로써 새로 합성된 콜라겐 양을 측정하였다. Procollagen type I C-peptide ELA kit (TaKaRa, cat. # MK101) was used to measure the amount of collagen synthesis released into the media from fibroblasts. Before using KIT, human fibroblasts cell line (ATCC, CRL-2310) was inoculated in a 24 well plate (24 well plate, Corning) at a concentration of 1 × 10 4 cells / ml. Medium was used DMEM (Dubelcco'S Modified Eagle Medium, BRL, USA) containing 10% FBS (bovine serum). After 24 hours of inoculation, 10 µl of the test sample was added to a concentration of 50 µg / ml and incubated in a 37%, 5% CO 2 incubator for 24 hours. The cultured medium was transferred to an E-tube and centrifuged for 30 seconds at 15,000 rpm. The supernatant of each well was collected and the amount of newly synthesized collagen was measured by measuring the amount of procollagen type I C-peptide (PIP) using a kit (Takara, Japan).
실시 후 ELISA reader(sunrise, Austria)로 흡광도는 450nm에서 측정하였다. 이때 비타민 C를 첨가한 것을 양성 대조군으로 같은 방법으로 실험을 진행하여 상대적인 흡광도의 차이로부터 콜라겐 생성량을 비교하였다. 대조군으로 사용된 비타민 C는 섬유아세포의 활성을 도와 콜라겐 합성을 촉진시켜주는 물질이다. 그 결과를 표6에 나타내었다. After implementation, the absorbance was measured at 450 nm with ELISA reader (sunrise, Austria). At this time, the experiment was conducted in the same manner as the positive control with the addition of vitamin C to compare the amount of collagen production from the difference in relative absorbance. Vitamin C used as a control is a substance that promotes collagen synthesis by helping the activity of fibroblasts. The results are shown in Table 6.
표 6. 혼합 추출물의 type Ⅰ 콜라겐 생합성량Table 6. Type I Collagen Biosynthesis of Mixed Extracts
상기 표 6에 나타난 결과에서 알 수 있듯이, 생약추출 혼합물을 처리하지 않은 대조군과 비교하여, 생약추출 혼합물이 처리된 실험군의 경우 매우 높은 type Ⅰ 콜라겐 생합성량을 나타낸다. 또한, 비타인 C를 처리한 대조군에 못지않은 효과를 나타낸다. 또한, 가감천금단과 가감경옥고 가감홍옥산을 각각 처리한 실험군에 비하여 세가지 생약추출 혼합물을 함께 처리한 실험군이 보다 월등한 type Ⅰ 콜라겐 생합성량를 나타낸다. 생약추출 혼합물의 농도가 증가할수록 type Ⅰ 콜라겐 생합성량도 증가한다. As can be seen from the results shown in Table 6, the experimental group treated with the herbal extract mixture shows a very high type I collagen biosynthesis compared to the control group without the herbal extract mixture. In addition, it shows the same effect as the control group treated with Vine C. In addition, the experimental group treated with the three herbal extract mixtures showed better type I collagen biosynthesis than the experimental group treated with Gagamcheon Forbidden and Gagam Gyeongokgo. As the concentration of herbal extract mixture increases, the amount of type I collagen biosynthesis increases.
실험예Experimental Example 7. 7. TypeType Ⅰ 콜라겐 Ⅰ Collagen mRNAmRNA 발현량 조사 Expression level investigation
상기 실시예로부터 얻어진 혼합 추출물에 대하여 type I 콜라겐 유전자의 발현 정도를 측정하기 위하여 RT-PCR(Reverse Transcription -Polymerase Chain Reaction)을 실시하였다. 인간 정상 섬유아세포(ATCC-2706)를 60mm 배양접시에 1 x 106의 밀도로 10% 소혈청(Gibco/BRL)을 포함하는 DMEM 배지(Gibco/BRL)에서 37℃, 5% CO2 배양기에서 하루 동안 키웠다. 그 후 혈청이 2% 첨가된 배지로 교환해 주고 시료를 농도별로 첨가하여 24시간 동안 37℃에서 배양한다. 그 후, 세포로부터 트라이졸 시약(Trizole reagent) (Gibco/BRL)을 이용한 구아니디움 티오시아네이트-페놀-클로로포름 추출 방법 (Guanidium thiocyanate-phenol- chloroform extraction)으로 토탈 RNA를 분리하였다. RT-PCR을 하기 위해 위의 방법으로 얻어진 RNA에 RNA 분해 효소가 없는 DNA 분해 효소 (RNase-free DNase, Promega)를 37℃에서 30분 동안 처리하여 DNA의 오염을 제거하였으며 페놀/클로로포름 추출법과 에탄올 침전을 통해 순수 RNA를 얻었다. RT-PCR (Reverse Transcription-Polymerase Chain Reaction) was performed to measure the expression level of the type I collagen gene with respect to the mixed extract obtained from the above example. Human Normal Fibroblasts (ATCC-2706) in DMEM medium (Gibco / BRL) containing 10% bovine serum (Gibco / BRL) at a density of 1 × 10 6 in a 60 mm culture dish in 37 ° C., 5% CO 2 incubator. Raised for a day. Thereafter, the cells were exchanged with a medium containing 2% serum, and samples were added at different concentrations and incubated at 37 ° C for 24 hours. Then, total RNA was isolated from the cells by guanidium thiocyanate-phenol-chloroform extraction using Trizole reagent (Gibco / BRL). In order to perform RT-PCR, the RNA obtained by the above method was treated with RNA degrading enzyme-free DNAase (RNase-free DNase, Promega) at 37 ° C for 30 minutes to remove DNA contamination, phenol / chloroform extraction method and ethanol. Precipitation gave pure RNA.
1㎍의 RNA를 올 인 원 RT/PCR 키트 (All in one RT/PCR kit, Superbio)를 사용하여 RT-PCR를 실시하였다. 대조군으로 베타-엑틴을 사용하였으며 RT-PCR에 사용된 type I 콜라겐의 프라이머(primer)는 서열번호 1과 서열번호 2로 구성되어있고, 베타-엑틴의 프라이머는 서열번호 3 과 서열번호 4로 구성되어있다. 반응 조건은 type I 콜라겐은 94℃ 1분, 62℃ 1분, 72℃ 1분, 30사이클이며, 베타-엑틴은 95℃ 1분, 62℃ 1분, 72℃ 1분, 22사이클이며, PCR 생산물은 1.5%(w/v) 아가로즈(agarose, Sigma사) 겔에 전기영동하여 겔 이미지 분석기(Biorad)로 정량하였다. 대조군으로 사용된 비타민 C는 섬유아세포의 활성을 도와 콜라겐 합성을 촉진시켜주는 물질이다. 그 결과를 표 8에 나타내었다.RT-PCR was performed using 1 μg of RNA using an All in one RT / PCR kit (Superbio). Beta-actin was used as a control, and the primer of type I collagen used in RT-PCR was composed of SEQ ID NO: 1 and SEQ ID NO: 2, and the primer of beta-actin was composed of SEQ ID NO: 3 and SEQ ID NO: 4 It is. The reaction conditions were type I collagen at 94 ° C for 1 minute, 62 ° C for 1 minute, 72 ° C for 1 minute, and 30 cycles, for beta-actin at 95 ° C for 1 minute, 62 ° C for 1 minute, 72 ° C for 1 minute, and 22 cycles for PCR. The product was quantified by a gel image analyzer (Biorad) by electrophoresis on a 1.5% (w / v) agarose (agarose, Sigma) gel. Vitamin C used as a control is a substance that promotes collagen synthesis by helping the activity of fibroblasts. The results are shown in Table 8.
표 7. 프라이머Table 7. Primers
표 8. Table 8.
상기 표 8에서 나타난 결과에서 알 수 있듯이, 생약추출 혼합물을 처리하지 않은 대조군과 비교하여, 생약추출 혼합물이 처리된 실험군의 경우 매우 높은 type Ⅰ 콜라겐 발현양을 나타낸다. 또한, 비타인 C를 처리한 대조군에 못지않은 효과를 나타낸다. 또한, 가감천금단과 가감경옥고 가감홍옥산을 각각 처리한 실험군에 비하여 세가지 생약추출 혼합물을 함께 처리한 실험군이 보다 월등한 type Ⅰ 콜라겐 발현양을 나타낸다. 생약추출 혼합물의 농도가 증가할수록 type Ⅰ 콜라겐 발현양도 증가한다. 이러한 결과는 상기 표6에서 나타난 결과와도 일치한다. As can be seen from the results shown in Table 8, compared to the control group not treated with the herbal extract mixture, the experimental group treated with the herbal extract mixture shows a very high type I collagen expression. In addition, it shows the same effect as the control group treated with Vine C. In addition, the experimental group treated with three herbal extract mixtures showed more superior type I collagen expression than the experimental group treated with Gagamcheon Forbidden and Gagam Gyeongokgo Gagam Hongoksan, respectively. As the concentration of herbal extract mixture increases, the amount of type I collagen expression increases. This result is also consistent with the result shown in Table 6 above.
제형예Formulation example 및 And 비교예Comparative example
하기 표의 조성비를 가지는 화장료 조성물에 본 발명 생약추출 혼합물이 포함된 제형예 및 생약추출 혼합물이 포함되지 않은 비교예를 제조하였다.In the cosmetic composition having a composition ratio of the following table, a formulation example including the inventive herbal extract mixture and a comparative example without the herbal extract mixture were prepared.
제형예Formulation example 및 And 비교예Comparative example 1. One.
하기 표에 나타난 바와 같이 유연 화장수(스킨)을 통상의 방법에 따라 제조하였다.A flexible lotion (skin) was prepared according to a conventional method as shown in the table below.
제형예Formulation example 및 And 비교예Comparative example 2. 2.
하기 표에 나타난 바와 같이 영양화장수(로션)을 통상의 방법에 따라 제조하였다. Nutrients (lotions) were prepared according to a conventional method as shown in the following table.
제형예Formulation example 및 And 비교예3Comparative Example 3
하기 표에 나타난 바와 같이 영양크림을 통상의 방법에 따라 제조하였다. Nutritious cream was prepared according to a conventional method as shown in the following table.
제형예Formulation example 및 And 비교예Comparative example 4. 4.
하기 표에 나타난 바와 같이 에센스를 통상의 방법에 따라 제조하였다. Essences were prepared according to conventional methods as shown in the table below.
제형예Formulation example 및 And 비교예Comparative example 5. 5.
하기 표에 나타난 바와 같이 유화형 화운데이션을 통상의 방법에 따라 제조하였다. Emulsified foundations were prepared according to conventional methods as shown in the table below.
시험예Test Example 1. 주름 깊이 감소에 의한 피부 탄력도 개선 효과 측정 1. Measurement of skin elasticity improvement effect by reducing wrinkle depth
실험방법Experiment method
피부주름에 대한 혼합 추출물의 영향을 실험하기 위해 제형예 3을 여성 20명(평균 연령 42세)씩 2그룹으로 나누어 왼쪽 눈 가장자리에 하루에 세안 후 아침, 저녁 두 번 도포하였다. 비교예 3의 영양크림을 오른쪽 눈 가장자리에 도포하여 대조군으로 사용하였다. 적용 15일, 30일 후 피부 표면의 피부 주름 깊이를 Cutometer SEM 474(Courage+Khazaka electronic GmbH. Germany)에 의해 측정하였다. Cutometer SEM 474에 의한 피부 탄력도 측정은 주름의 깊이를 측정하는 것으로서, 값이 적을수록 탄력성이 좋은 것이다. 탄력도 값은 대조군에 비해 감소한 값을 %로 나타내었으며, 피검자 20명의 평균값을 표 9에 나타내었다. In order to test the effect of the mixed extract on the skin wrinkles, Formulation Example 3 was divided into two groups of 20 women (average age 42 years) and applied twice a day and then morning and evening to the left eye edge. Nourishing cream of Comparative Example 3 was applied to the right eye edge and used as a control. The skin wrinkle depth of the skin surface after 15 and 30 days of application was measured by Cutometer SEM 474 (Courage + Khazaka electronic GmbH. Germany). Skin elasticity measurement by Cutometer SEM 474 is a measure of the depth of wrinkles, the smaller the value is the better elasticity. The elasticity value was shown as a percentage decrease compared to the control, and the average value of 20 subjects is shown in Table 9.
실험 결과Experiment result
표. 9table. 9
표 9의 결과에서 나타나는 바와 같이, 생약추출 혼합물을 함유한 실시예의 피부탄력(주름깊이 감소)효과는 생약혼합 추출물을 함유하지 않는 15일 경과시에는 비교예에 비해 10배 이상 증가, 30일 경과시에는 18배 이상 증가함을 확인할 수 있 었다.As shown in the results of Table 9, the skin elasticity (decrease in wrinkle depth) of the embodiment containing the herbal extract mixture was increased by more than 10 times compared to the comparative example, 30 days after 15 days without containing the herbal mixture extract Poetry was found to increase more than 18 times.
시험예 2. 피부 상태 개선효과 확인 실험Experimental Example 2. Experiment to confirm the effect of improving skin condition
제형예 4와 비교예 4의 에센스에 대한 피부도포시 피부상태 개선효과를 확인하기 위하여 다음과 같은 임상 확인 실험을 하였다. 36~69세의 건강한 여성층으로서 30명씩 2그룹으로 나누어 안면 왼쪽 부분에는 처방예 4의 제형예 4의 에센스를, 안면 오른쪽 부분에는 비교예 4의 에센스를 매일 아침, 저녁 세안 후 피부에 1일 2회 4주간 도포한 후 피부상태 개선을 확인하기 위하여 피부상태 개선 정도를 측정하였다. (가) 피부의 탄력, 늘어짐에 대한 개선 효과 및 (나) 주름, 잔주름에 대한 개선 효과에 관해서 다음의 평점으로 판정하여, 30명의 평균점으로 평가하였다. 시험결과를 표10에 나타내었다.In order to confirm the skin condition improvement effect during the skin coating on the essence of Formulation Example 4 and Comparative Example 4, the following clinical confirmation experiment was carried out. Healthy females aged 36 to 69 years old, divided into two groups of 30 people, the essence of Formulation Example 4 of Formulation Example 4 on the left side of the face, and the essence of Comparative Example 4 on the right side of the face. After applying for 4 weeks, the degree of improvement of skin condition was measured to confirm the improvement of skin condition. (A) Improvement effect on skin elasticity and sagging, and (B) Improvement effect on wrinkles and fine lines were judged by the following ratings, and evaluated by an average score of 30 people. The test results are shown in Table 10.
표 10.Table 10.
(가) 피부의 탄력, 늘어짐에 대한 개선 효과의 평점 기준(A) Rating criteria for improvement effect on skin elasticity and sagging
(나) 주름, 잔주름에 대한 개선 효과의 평점 기준 (B) Rating criteria for improvement effect on wrinkles and fine lines
(다) 시험결과 (C) Test results
상기 표10의 결과에서 나타나는 바와 같이 제형예 4를 사용한 군에서는 (가) 와 (나) 양쪽 모두에서 비교예를 사용한 군과 비교할때 훨씬 뛰어난 피부 개선 효과가 확인되었다. As shown in the results of Table 10, in the group using Formulation Example 4, a much better skin improvement effect was confirmed in comparison with the group using the comparative example in both (A) and (B).
상기 상술한 바와 같이 본 발명에 따른 백지, 동과인, 천궁, 둥글레, 세신, 토과근, 도인, 목단피, 신이, 감송향 및 백강잠으로 이루어진 혼합 추출물('가감천금단')과 인삼, 지황 및 꿀로 이루어진 혼합추출물('가감경옥고'), 행인, 과루근 및 백봉령으로 이루어진 혼합 추출물('가감홍옥산')을 유효성분으로 함유하는 피부 노화 방지용 화장료 조성물은 피부에 대한 부작용 없이 안전하게 사용할 수 있다. 뿐만 아니라 세포증식 및 대사 활성 증진, 프리 라디칼 소거, 콜라겐 생산촉진에 의한 피부 주름 개선과 피부 탄력 개선을 통하여 피부 노화를 방지 및 개선한다. As described above, the mixed extract ('gagamcheon forbidden') and ginseng, jihwang and baekji, dongwain, cheonggung, roundle, sessin, earthen root, doujin, mokdanpi, shinyi, gamsonghyang and baekgangjam according to the present invention as described above Skin anti-aging cosmetic composition containing a mixed extract consisting of honey ('gagamyeongokgo'), almonds, fruit roots and baekbongyeong ('gagamhongoksan') as an active ingredient can be used safely without side effects on the skin. In addition, it prevents and improves skin aging by improving cell proliferation and metabolic activity, free radical scavenging, and improving skin wrinkles and skin elasticity by promoting collagen production.
<110> korea University industry and academy collaboration foundation <120> Cosmetic composition for preventing skin <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> RT-PCR primer 1 for type 1 collagen <400> 1 ctggcaaaga aggcggcaaa 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> RT-PCR primer 2 for type 1 collagen <400> 2 ctcaccacga tcaccactct 20 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> RT-PCR primer 3 for beta-actin <400> 3 gagaccttca acaccccagc c 21 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> RT-PCR primer 4 for beta-actin <400> 4 ggccatctct tgctcgaagt c 21 <110> korea University industry and academy collaboration foundation <120> Cosmetic composition for preventing skin <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> RT-PCR primer 1 for type 1 collagen <400> 1 ctggcaaaga aggcggcaaa 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> RT-PCR primer 2 for type 1 collagen <400> 2 ctcaccacga tcaccactct 20 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> RT-PCR primer 3 for beta-actin <400> 3 gagaccttca acaccccagc c 21 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> RT-PCR primer 4 for beta-actin <400> 4 ggccatctct tgctcgaagt c 21
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080071236A KR101059471B1 (en) | 2008-07-22 | 2008-07-22 | Cosmetic composition for skin aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080071236A KR101059471B1 (en) | 2008-07-22 | 2008-07-22 | Cosmetic composition for skin aging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100010316A true KR20100010316A (en) | 2010-02-01 |
| KR101059471B1 KR101059471B1 (en) | 2011-08-25 |
Family
ID=42085016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080071236A Active KR101059471B1 (en) | 2008-07-22 | 2008-07-22 | Cosmetic composition for skin aging |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101059471B1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011054855A1 (en) | 2010-10-28 | 2012-05-03 | Lg Display Co., Ltd. | Phosphorescent compound and organic electroluminescent device using the same |
| WO2013050697A2 (en) | 2011-10-03 | 2013-04-11 | Societe Industrielle Limousine D'application Biologique | Use of glucans obtained from prunus persica as an anti-aging cosmetic agent |
| KR20130070062A (en) * | 2011-12-19 | 2013-06-27 | (주)아모레퍼시픽 | Cosmetic composition for anti-oxidation or skin whintening containing extract of medicinal herbs mixture |
| KR101457068B1 (en) * | 2012-09-06 | 2014-10-31 | 권선진 | Method for manufacturing massage pack using collagen protein extracted out of pork rinds |
| WO2015170993A1 (en) * | 2014-05-06 | 2015-11-12 | Comvita Limited | A matrix-metalloproteinase (mmp) inhibitory extract and methods of use thereof |
| KR20160020064A (en) * | 2014-08-13 | 2016-02-23 | 정해윤 | Composition of beauty treatment comprising lysosome for old people |
| CN108064160A (en) * | 2014-09-19 | 2018-05-22 | 庆熙大学校产学协力团 | For treating and preventing the extract of the mixture containing moutan root bark, root of Dahurain angelica root and radix bupleuri root of nerve degenerative diseases or its fraction pharmaceutical composition as active component |
| CN110652475A (en) * | 2018-06-29 | 2020-01-07 | 伽蓝(集团)股份有限公司 | Application of nardostachys chinensis extract |
| KR20200008382A (en) * | 2018-07-16 | 2020-01-28 | 김미녀 | Natural and Herbal Cosmetic and the Method of making of it |
| KR102566925B1 (en) * | 2022-09-20 | 2023-08-14 | 주식회사 단정바이오 | A cosmetic composition comprising active ingredients of Magnolia Sieboldii, Magnolia Liliflora Flower, Cnidium Officinale Root, Benincasa Cerifera Seed, Prunus Persica (Peach) Kernel, and Poria Cocos |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173239A (en) * | 2014-08-29 | 2014-12-03 | 桐梓县农源中药材种植专业合作社 | Pure natural plant skin cream |
| KR101857543B1 (en) * | 2016-07-01 | 2018-05-15 | 광주여자대학교 산학협력단 | Cosmetic composition containing extract of mixed herbs for promoting of collagen synthesis |
| KR20240111493A (en) | 2023-01-10 | 2024-07-17 | 차혜영 | Composition for skin protection comprising Persicae Semen and Sparganii Rhizoma extract thereof as active ingredient |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100519154B1 (en) | 2003-01-10 | 2005-10-06 | 최상숙 | Antiageing and whitening cosmetics containing natural extracts |
-
2008
- 2008-07-22 KR KR1020080071236A patent/KR101059471B1/en active Active
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011054855A1 (en) | 2010-10-28 | 2012-05-03 | Lg Display Co., Ltd. | Phosphorescent compound and organic electroluminescent device using the same |
| DE102011054855B4 (en) | 2010-10-28 | 2019-07-11 | Lg Display Co., Ltd. | Phosphorescent compound and organic electroluminescent device using the same |
| WO2013050697A2 (en) | 2011-10-03 | 2013-04-11 | Societe Industrielle Limousine D'application Biologique | Use of glucans obtained from prunus persica as an anti-aging cosmetic agent |
| KR20130070062A (en) * | 2011-12-19 | 2013-06-27 | (주)아모레퍼시픽 | Cosmetic composition for anti-oxidation or skin whintening containing extract of medicinal herbs mixture |
| KR101457068B1 (en) * | 2012-09-06 | 2014-10-31 | 권선진 | Method for manufacturing massage pack using collagen protein extracted out of pork rinds |
| CN106659744A (en) * | 2014-05-06 | 2017-05-10 | 康维他有限公司 | Matrix metalloproteinase (MMP) inhibitory extracts and methods of use thereof |
| WO2015170993A1 (en) * | 2014-05-06 | 2015-11-12 | Comvita Limited | A matrix-metalloproteinase (mmp) inhibitory extract and methods of use thereof |
| CN112826785A (en) * | 2014-05-06 | 2021-05-25 | 康维他有限公司 | Cosmetic skin care product comprising honey extract and use thereof |
| US11273121B2 (en) | 2014-05-06 | 2022-03-15 | Comvita Limited | Matrix-metalloproteinase (MMP) inhibitory extract and methods of use thereof |
| CN112826785B (en) * | 2014-05-06 | 2023-08-01 | 康维他有限公司 | Cosmetic skin care product comprising honey extract and use thereof |
| KR20160020064A (en) * | 2014-08-13 | 2016-02-23 | 정해윤 | Composition of beauty treatment comprising lysosome for old people |
| CN108064160A (en) * | 2014-09-19 | 2018-05-22 | 庆熙大学校产学协力团 | For treating and preventing the extract of the mixture containing moutan root bark, root of Dahurain angelica root and radix bupleuri root of nerve degenerative diseases or its fraction pharmaceutical composition as active component |
| CN110652475A (en) * | 2018-06-29 | 2020-01-07 | 伽蓝(集团)股份有限公司 | Application of nardostachys chinensis extract |
| KR20200008382A (en) * | 2018-07-16 | 2020-01-28 | 김미녀 | Natural and Herbal Cosmetic and the Method of making of it |
| KR102566925B1 (en) * | 2022-09-20 | 2023-08-14 | 주식회사 단정바이오 | A cosmetic composition comprising active ingredients of Magnolia Sieboldii, Magnolia Liliflora Flower, Cnidium Officinale Root, Benincasa Cerifera Seed, Prunus Persica (Peach) Kernel, and Poria Cocos |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101059471B1 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101059471B1 (en) | Cosmetic composition for skin aging | |
| TWI381834B (en) | Abnormal protein removal composition | |
| TWI857919B (en) | Anti-inflammatory agents and cosmetics | |
| KR20170137564A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170137552A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20090130584A (en) | Cosmetic composition for skin whitening and wrinkle improvement containing complex herbal extract as an active ingredient | |
| KR100776346B1 (en) | Composition with anti-dandruff, anti-inflammatory activity, containing nasturtium, succinate, sewage, and half-mixed herbal extract | |
| KR102721819B1 (en) | Composition for skin moisturizing or enhancing skin barrier containing the polysaccharide from the root of Camellia sinensis | |
| KR20170137465A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR100769302B1 (en) | Skin external composition having the effect of treating and improving wound healing and skin pruritus containing herbal extract | |
| KR102051417B1 (en) | The cosmetic composition for the prevention and improvement of striae distensae | |
| KR20170136919A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170137405A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170137412A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170136389A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170137549A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170136913A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| JP2001233727A (en) | Cosmetics | |
| KR102198589B1 (en) | Whitening cosmetic composition containing Rhodiola rosea, Selaginella tamariscina, Celosia cristata and Artemisia princeps complex extract and phytol | |
| KR20140114709A (en) | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract | |
| KR20100092922A (en) | A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome | |
| KR101230588B1 (en) | Cosmetic composition containing natural vitamin and plant complex extract | |
| KR20170136933A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170137436A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20140115229A (en) | Composition comprising oriental herbal extracts having antioxidant or whitening effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20080722 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100830 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20110401 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20110802 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20110819 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20110819 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20140729 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140729 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20150728 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150728 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20160805 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160805 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170804 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20180731 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180731 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200730 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210712 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220805 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230705 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240710 Start annual number: 14 End annual number: 14 |